1 | C (migalastat) | 1件: Migalastat Migalastat | 1件: D10359
D10359
| - | - | 1件: 19 19 |
2 | C-028380 | - | - | - | - | 1件: 106 106 |
3 | C-11 PiB | 1件: Pittsburgh Compound B Pittsburgh Compound B | - | - | - | 1件: 127 127 |
4 | C-82 Topical Gel, 1% | - | - | - | - | 1件: 51 51 |
5 | C-kit+ cells | - | - | - | - | 1件: 211 211 |
6 | C-Stem™ AMT Femoral Component (standard and high off-set variants) | - | - | - | - | 1件: 46 46 |
7 | C-Trelin OD Tab(5mg Taltirelin Hydrate) | - | - | - | - | 1件: 18 18 |
8 | C-TYPE NATRIURETIC PEPTIDE CONJUGATED TO MULTI-ARM POLYETHYLENE GLYCOL CARRIER THROUGH A CLEAVABLE LINKER | 1件: Polyethylene glycol Polyethylene glycol | 1件: D03370
D03370
| - | - | 1件: 276 276 |
9 | C. albicans | - | - | - | - | 1件: 46 46 |
10 | C01CA04 - Dopamina | 1件: Dopamine Dopamine | 2件: D00633
D00633
,
D07870
| 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 299 299 |
11 | C01EB18 | - | - | - | - | 1件: 58 58 |
12 | C03XA01 | - | - | - | - | 2件: 67 67, 72 |
13 | C07AB07 | - | - | - | - | 1件: 86 86 |
14 | C09 | - | - | - | - | 1件: 66 66 |
15 | C1 ESTERASE INHIBITOR (HUMAN) | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 |
16 | C1 Esterase Inhibitor Human | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 |
17 | C1 inhibitor | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 |
18 | C1 inhibitor concentrate | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 |
19 | C1-esterase inhibitor (Cinryze) | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 13 13 |
20 | C1-esterase inhibitor [recombinant] (C1-INH-R) | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 |
21 | C1-INH | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 |
22 | C105 | - | - | - | - | 1件: 13 13 |
23 | C10AA05 | - | - | - | - | 1件: 46 46 |
24 | C10AB02 | - | - | - | - | 1件: 94 94 |
25 | C11-methionine | 1件: Methionine Methionine | 2件: D00019
D00019
,
D04983
| - | - | 1件: 84 84 |
26 | C21 | - | - | - | - | 2件: 51 51, 85 |
27 | C225 | - | - | - | - | 2件: 51 51, 86 |
28 | C326, IL-6 Inhibitory Avimer protein | - | - | - | - | 1件: 96 96 |
29 | C5 inh MAb, SKY59, RO/CH7092230 | - | - | - | - | 2件: 62 62, 109 |
30 | C5 Inhibitor | - | - | - | - | 1件: 62 62 |
31 | CA | - | - | - | - | 1件: 234 234 |
32 | CA2 | - | - | - | - | 1件: 271 271 |
33 | Cabaletta | 1件: Trehalose Trehalose | - | - | - | 2件: 18 18, 113 |
34 | Cabaletta for IV infusion once weekly during 24 weeks | 1件: Trehalose Trehalose | - | - | - | 1件: 18 18 |
35 | Cabaser | - | - | - | - | 1件: 6 6 |
36 | Cabaseril | - | - | - | - | 1件: 6 6 |
37 | Cabaseril, 1,0 mg Tablette | - | - | - | - | 1件: 6 6 |
38 | Cabaseril, 2,0 mg Tablette | - | - | - | - | 1件: 6 6 |
39 | CABERGOLINA | 1件: Cabergoline Cabergoline | 1件: D00987
D00987
| 2件: DRD2 DRD2, PRL 💬 | 12件: Alcoholism Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬 | 2件: 6 6, 75 |
40 | Cabergoline | 1件: Cabergoline Cabergoline | 1件: D00987
D00987
| 2件: DRD2 DRD2, PRL 💬 | 12件: Alcoholism Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬 | 3件: 6 6, 74, 75 |
41 | CABERGOLINE TEVA | 1件: Cabergoline Cabergoline | 1件: D00987
D00987
| 2件: DRD2 DRD2, PRL 💬 | 12件: Alcoholism Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 75 75 |
42 | CABLIVI | 1件: Caplacizumab Caplacizumab | 1件: D11160
D11160
| 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 |
43 | Cablivi® | 1件: Caplacizumab Caplacizumab | 1件: D11160
D11160
| 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 |
44 | Cabozantinib | 1件: Cabozantinib Cabozantinib | 1件: D10062
D10062
| 3件: AXL AXL, KDR, MET 💬 | 25件: Adherens junction Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Calcium signaling pathway, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, EGFR tyrosine kinase inhibitor resistance, Epithelial cell signaling in Helicobacter pylori infection, Fluid shear stress and atherosclerosis, Focal adhesion, Gastric cancer, Hepatocellular carcinoma, MAPK signaling pathway, Malaria, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, PI3K-Akt signaling pathway, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Renal cell carcinoma, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 34 34 |
45 | CADD-Legacy ambulatory infusion pump | - | - | - | - | 1件: 6 6 |
46 | CADD-Legacy® 1400 ambulatory infusion pump | - | - | - | - | 1件: 6 6 |
47 | CAEL-101 | - | - | - | - | 1件: 28 28 |
48 | Caffeic acid tablets | - | - | - | - | 1件: 63 63 |
49 | Caffeine | 1件: Caffeine Caffeine | 2件: D00528
D00528
,
D01453
| 11件: ADORA1 ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 | 22件: Alcoholism Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
50 | Caffeine 100 mg | 1件: Caffeine Caffeine | 2件: D00528
D00528
,
D01453
| 11件: ADORA1 ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 | 22件: Alcoholism Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 96 96, 97 |
51 | Caffeine 100-200 mg BID | 1件: Caffeine Caffeine | 2件: D00528
D00528
,
D01453
| 11件: ADORA1 ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 | 22件: Alcoholism Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
52 | Caffeine alkaloid | 1件: Caffeine Caffeine | 2件: D00528
D00528
,
D01453
| 11件: ADORA1 ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 | 22件: Alcoholism Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
53 | Calcichew D3 | - | - | - | - | 1件: 274 274 |
54 | Calcichew D3 Forte | - | - | - | - | 1件: 113 113 |
55 | Calcichew tablets | - | - | - | - | 1件: 274 274 |
56 | CALCIFEDIOL | 1件: Calcifediol Calcifediol | 1件: D00122
D00122
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 113 113 |
57 | Calciferol | 1件: Vitamin D Vitamin D | - | - | - | 1件: 49 49 |
58 | Calcineurin Inhibitors | - | - | - | - | 1件: 50 50 |
59 | Calcineurin inhibitors maintenance | - | - | - | - | 1件: 67 67 |
60 | Calcio | 1件: Calcium Calcium | - | - | - | 4件: 13 13, 96, 97, 274 |
61 | Calcio carbonato | 2件: Calcium Calcium, Calcium carbonate | 2件: D00932
D00932
,
D10802
| - | - | 1件: 274 274 |
62 | CALCIO CARBONATO/COLECALCIFEROLO | 2件: Calcium Calcium, Calcium carbonate | 2件: D00932
D00932
,
D10802
| - | - | 1件: 274 274 |
63 | CALCIO FOLINATO DC.IT | 1件: Calcium Calcium | - | - | - | 1件: 13 13 |
64 | Calcipotriene | 1件: Calcipotriol Calcipotriol | 1件: D01125
D01125
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 51 51 |
65 | CALCIPOTRIOL | 1件: Calcipotriol Calcipotriol | 1件: D01125
D01125
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 36 36 |
66 | Calcitonin | - | - | - | - | 1件: 225 225 |
67 | CALCITONIN (SALMON) | 1件: Salmon, unspecified Salmon, unspecified | - | - | - | 1件: 225 225 |
68 | Calcitonin nasal spray (salmon) | 1件: Salmon, unspecified Salmon, unspecified | - | - | - | 2件: 96 96, 97 |
69 | Calcitriol | 1件: Calcitriol Calcitriol | 1件: D00129
D00129
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 9件: 18 18, 37, 46, 49, 66, 96, 158, 235, 326 |
70 | Calcitriol & Calcium | 2件: Calcitriol Calcitriol, Calcium | 1件: D00129
D00129
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 235 235 |
71 | Calcium | 1件: Calcium Calcium | - | - | - | 30件: 3 3, 6, 13, 15, 19, 46, 49, 51, 53, 56, 68, 75, 79, 84, 93, 94, 95, 96, 97, 186, 214, 215, 222, 224, 235, 256, 265, 274, 298, 299 |
72 | Calcium and cholecalciferol | 2件: Calcium Calcium, Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 46 46 |
73 | Calcium and Vitamin D combination | 2件: Calcium Calcium, Vitamin D | - | - | - | 1件: 13 13 |
74 | Calcium carbonate | 2件: Calcium Calcium, Carbonate ion | - | - | - | 8件: 13 13, 19, 46, 53, 75, 96, 235, 299 |
75 | Calcium carbonate and alphacalcidol | 2件: Calcium Calcium, Carbonate ion | - | - | - | 1件: 235 235 |
76 | Calcium carbonate D | 2件: Calcium Calcium, Carbonate ion | - | - | - | 1件: 53 53 |
77 | Calcium Channel Blockers | 1件: Calcium Calcium | - | - | - | 1件: 51 51 |
78 | Calcium citrate | 2件: Calcium Calcium, Calcium citrate | 1件: D00933
D00933
| - | - | 3件: 46 46, 84, 235 |
79 | Calcium Citrate with Vitamin D2 | 3件: Calcium Calcium, Calcium citrate, Ergocalciferol | 2件: D00187
D00187
,
D00933
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 84 84 |
80 | Calcium D3 | 1件: Calcium Calcium | - | - | - | 1件: 274 274 |
81 | CALCIUM D3 SANDOZ - 1000 MG + 880 U.I. COMPRESSE EFFERVESCENTI 30 COMPRESSE DIVISIBILI | 1件: Calcium Calcium | - | - | - | 1件: 274 274 |
82 | Calcium gluconate | 2件: Calcium Calcium, Calcium gluconate | 1件: D00935
D00935
| - | - | 3件: 214 214, 215, 235 |
83 | Calcium lactate | 2件: Calcium Calcium, Calcium lactate | 2件: D00936
D00936
,
D02254
| - | - | 1件: 235 235 |
84 | Calcium levofolinate | 1件: Calcium Calcium | - | - | - | 1件: 13 13 |
85 | Calcium rosuvastatin | 2件: Calcium Calcium, Rosuvastatin | 2件: D01915
D01915
,
D08492
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 79 79 |
86 | Calcium, Dietary | 1件: Calcium Calcium | - | - | - | 1件: 298 298 |
87 | CALD HR-D (High-Risk, Regimen C) | - | - | - | - | 5件: 19 19, 20, 125, 234, 326 |
88 | CALD HR-D (High-Risk, Regimen D) | - | - | - | - | 5件: 19 19, 20, 125, 234, 326 |
89 | CALD SR-A (Standard-Risk, Regimen A) | - | - | - | - | 5件: 19 19, 20, 125, 234, 326 |
90 | CALD SR-B (Standard-Risk, Regimen B) | - | - | - | - | 5件: 19 19, 20, 125, 234, 326 |
91 | Calfactant | 1件: Calfactant Calfactant | 1件: D03317
D03317
| - | - | 1件: 299 299 |
92 | Calogen | - | - | - | - | 1件: 2 2 |
93 | Caltrate | - | - | - | - | 1件: 97 97 |
94 | Caltrate Pill | - | - | - | - | 1件: 96 96 |
95 | Calvan® 100 mg | - | - | - | - | 1件: 8 8 |
96 | CALY-002 | - | - | - | - | 1件: 98 98 |
97 | CAM-3001 | 1件: Mavrilimumab Mavrilimumab | 1件: D09930
D09930
| 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 46 46 |
98 | CAM2043 | - | - | - | - | 1件: 51 51 |
99 | Campath | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 12件: 19 19, 20, 49, 51, 60, 62, 65, 164, 234, 283, 285, 326 |
100 | Campath -1H | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 1件: 65 65 |
101 | Campath 1H | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 4件: 60 60, 65, 164, 285 |
102 | Campath, Busulfan, Clofarabine | 2件: Busulfan Busulfan, Clofarabine | 2件: D00248
D00248
,
D03546
| 3件: POLA1 POLA1, POLA2, RRM1 💬 | 6件: DNA replication DNA replication, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 326 326 |
103 | Campath, Chemo and/or TBI Allo SCT | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 3件: 60 60, 62, 283 |
104 | Campath, Fludarabine, Cyclophosphamide | 2件: Cyclophosphamide Cyclophosphamide, Fludarabine | 4件: D00287
D00287
,
D01907
,
D07760
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 284 |
105 | Campath-1H | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 6件: 19 19, 20, 60, 234, 285, 326 |
106 | CAMPATH-1H (Alemtuzumab) | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 1件: 60 60 |
107 | Canakinumab | 1件: Canakinumab Canakinumab | 1件: D09315
D09315
| 1件: IL1B IL1B 💬 | 44件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection 💬 | 10件: 46 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 |
108 | Canakinumab (ACZ885) | 1件: Canakinumab Canakinumab | 1件: D09315
D09315
| 1件: IL1B IL1B 💬 | 44件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection 💬 | 1件: 106 106 |
109 | Canakinumab (company code: ACZ885D) | 1件: Canakinumab Canakinumab | 1件: D09315
D09315
| 1件: IL1B IL1B 💬 | 44件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection 💬 | 1件: 106 106 |
110 | Canakinumab (investigational) | 1件: Canakinumab Canakinumab | 1件: D09315
D09315
| 1件: IL1B IL1B 💬 | 44件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection 💬 | 1件: 46 46 |
111 | Canakinumab (proposed) | 1件: Canakinumab Canakinumab | 1件: D09315
D09315
| 1件: IL1B IL1B 💬 | 44件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection 💬 | 1件: 46 46 |
112 | Canakinumab (WHO approval pending) | 1件: Canakinumab Canakinumab | 1件: D09315
D09315
| 1件: IL1B IL1B 💬 | 44件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection 💬 | 1件: 106 106 |
113 | Canakinumab Injection | 1件: Canakinumab Canakinumab | 1件: D09315
D09315
| 1件: IL1B IL1B 💬 | 44件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection 💬 | 1件: 46 46 |
114 | Canakinumab Injection [Ilaris] | 1件: Canakinumab Canakinumab | 1件: D09315
D09315
| 1件: IL1B IL1B 💬 | 44件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection 💬 | 1件: 113 113 |
115 | Candesartan | 1件: Candesartan Candesartan | 1件: D00522
D00522
| 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 58 58, 67 |
116 | Candesartan and Cilnidipine | 2件: Candesartan Candesartan, Cilnidipine | 2件: D00522
D00522
,
D01173
| 6件: AGTR1 AGTR1, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 49件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Apelin signaling pathway, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Huntington disease, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prion disease, Renin secretion, Renin-angiotensin system, Retrograde endocannabinoid signaling, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 67 67 |
117 | Candesartan plus non-CCB agents | 1件: Candesartan Candesartan | 1件: D00522
D00522
| 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 67 67 |
118 | Cannabidiol | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 18件: 6 6, 8, 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271 |
119 | Cannabidiol (CBD) | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 7件: 6 6, 13, 140, 144, 145, 156, 158 |
120 | Cannabidiol , synthetic form | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 96 96 |
121 | Cannabidiol / Dronabinol capsule 5 mg+2,5 mg | 2件: Cannabidiol Cannabidiol, Dronabinol | 2件: D00306
D00306
,
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
122 | Cannabidiol Botanical Drug Substance (CBD BDS) | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
123 | Cannabidiol capsule 5 mg | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
124 | Cannabidiol Oral Solution | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 4件: 140 140, 144, 145, 193 |
125 | Cannabidiol Oral Solution, is known as Epidyolex 100 mg/mL oral solution and is the approved name in the EU. Epidiolex (cannabidiol) oral solution is the approved name in the US. | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 158 158 |
126 | Cannabidiol tablet 10 mg | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 2件: 46 46, 271 |
127 | Cannabidiol vaginal suppository | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 226 226 |
128 | Cannabidiolo | - | - | - | - | 1件: 156 156 |
129 | Cannabidiolo (CBD) | - | - | - | - | 1件: 156 156 |
130 | CANNABINOL | 1件: Cannabinol Cannabinol | - | - | - | 1件: 36 36 |
131 | Cannabinol (CBN) | 1件: Cannabinol Cannabinol | - | - | - | 1件: 36 36 |
132 | Cannabis | 1件: Medical Cannabis Medical Cannabis | - | - | - | 9件: 2 2, 6, 13, 19, 46, 90, 96, 97, 271 |
133 | Cannabis Based Medicine Extract (Sativex) | 1件: Medical Cannabis Medical Cannabis | - | - | - | 1件: 13 13 |
134 | Cannabis Oil | 1件: Medical Cannabis Medical Cannabis | - | - | - | 1件: 6 6 |
135 | Cannabis Sativa extract Oromucosal spray | 1件: Medical Cannabis Medical Cannabis | - | - | - | 1件: 2 2 |
136 | Cannabis sativa L., folium cum flore | 1件: Medical Cannabis Medical Cannabis | - | - | - | 1件: 19 19 |
137 | Cannabis, Medical | 1件: Medical Cannabis Medical Cannabis | - | - | - | 5件: 2 2, 6, 13, 96, 97 |
138 | Cannador | - | - | - | - | 1件: 13 13 |
139 | CAP-1002 | 1件: CAP-1002 CAP-1002 | - | - | - | 1件: 113 113 |
140 | Capacity of muscular oxygen extraction | 1件: Oxygen Oxygen | 1件: D00003
D00003
| - | - | 1件: 13 13 |
141 | Capecitabine | 1件: Capecitabine Capecitabine | 1件: D01223
D01223
| 1件: TYMS TYMS 💬 | 4件: Antifolate resistance Antifolate resistance, Metabolic pathways, One carbon pool by folate, Pyrimidine metabolism 💬 | 1件: 94 94 |
142 | CAPILLAREMA | - | - | - | - | 1件: 51 51 |
143 | CAPLACIZUMAB | 1件: Caplacizumab Caplacizumab | 1件: D11160
D11160
| 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 |
144 | Caplacizumab (ALX-0081) | 1件: Caplacizumab Caplacizumab | 1件: D11160
D11160
| 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 |
145 | Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081) | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: D11160
D11160
| 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 |
146 | Caplacizumab (an anti-von Willebrand Factor Nanobody) | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: D11160
D11160
| 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 |
147 | Caprylic Triglyceride | 1件: Tricaprylin Tricaprylin | - | - | - | 1件: 13 13 |
148 | Capsaicin | 1件: Capsaicin Capsaicin | 1件: D00250
D00250
| 1件: TRPV1 TRPV1 💬 | 2件: Inflammatory mediator regulation of TRP channels Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 5件: 2 2, 6, 19, 86, 226 |
149 | Capsaicin Challenge | 1件: Capsaicin Capsaicin | 1件: D00250
D00250
| 1件: TRPV1 TRPV1 💬 | 2件: Inflammatory mediator regulation of TRP channels Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 2 2 |
150 | Capsaicin vapor | 1件: Capsaicin Capsaicin | 1件: D00250
D00250
| 1件: TRPV1 TRPV1 💬 | 2件: Inflammatory mediator regulation of TRP channels Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 |
151 | Capsule di prednisone | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 |
152 | Capsule endoscopy | - | - | - | - | 1件: 96 96 |
153 | Capsule fecal microbiota material (cap-FMT) | - | - | - | - | 1件: 96 96 |
154 | Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: D00059
D00059
,
D00558
,
D00781
| 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
155 | Capsules with 160 mg Teavigo (at least 94% EGCG) | 1件: Epigallocatechin gallate Epigallocatechin gallate | - | - | - | 1件: 13 13 |
156 | Captopril | 1件: Captopril Captopril | 1件: D00251
D00251
| 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 2件: 17 17, 86 |
157 | CAPTURE | 1件: Bifenthrin Bifenthrin | - | - | - | 2件: 6 6, 46 |
158 | Carbaglu | 1件: Carglumic acid Carglumic acid | 1件: D07130
D07130
| 1件: CPS1 CPS1 💬 | 6件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Arginine biosynthesis, Biosynthesis of amino acids, Carbon metabolism, Metabolic pathways, Nitrogen metabolism 💬 | 2件: 245 245, 246 |
159 | Carbamazepine | 1件: Carbamazepine Carbamazepine | 1件: D00252
D00252
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 2件: 13 13, 231 |
160 | Carbasalate calcium | 2件: Calcium Calcium, Carbaspirin calcium | 1件: D03385
D03385
| - | - | 1件: 46 46 |
161 | Carbetocin | 1件: Carbetocin Carbetocin | 1件: D07229
D07229
| 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 1件: 193 193 |
162 | Carbidopa | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 9件: 2 2, 4, 6, 13, 17, 90, 140, 164, 201 |
163 | CARBIDOPA (CD) | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
164 | CARBIDOPA (FU) | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
165 | Carbidopa 20 mg | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
166 | Carbidopa 200mg oral dose | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 2件: 6 6, 17 |
167 | Carbidopa 27.5 mg | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
168 | Carbidopa 65 mg capsule | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
169 | Carbidopa and Levodopa 25mg/100mg | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
170 | Carbidopa and Levodopa Controlled Release Tablets | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
171 | Carbidopa and Levodopa Tablets, USP | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
172 | CARBIDOPA ANIDRA | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
173 | CARBIDOPA FU | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
174 | CARBIDOPA INN | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
175 | CARBIDOPA LEVODOPA | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
176 | CARBIDOPA MONOHYDRATE | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
177 | Carbidopa Pill | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
178 | Carbidopa, levodopa, entacapone | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: D00059
D00059
,
D00558
,
D00781
| 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
179 | Carbidopa- Levodopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
180 | Carbidopa-4'-Monophosphate | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
181 | Carbidopa-levodopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 3件: 2 2, 4, 6 |
182 | Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
183 | Carbidopa/l-dopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
184 | Carbidopa/l-dopa/entacapone | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: D00059
D00059
,
D00558
,
D00781
| 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
185 | Carbidopa/levodopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
186 | Carbidopa/levodopa, as prescribed by treating physician | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
187 | Carbidopa/Levodopa, immediate release | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
188 | Carbidopa/Levodopa/Entacapone | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: D00059
D00059
,
D00558
,
D00781
| 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
189 | Carbidopamonohydraat | - | - | - | - | 1件: 6 6 |
190 | CARBODOPA LEVADOPA | - | - | - | - | 1件: 6 6 |
191 | Carbodopa/levadopa | - | - | - | - | 1件: 6 6 |
192 | Carbohydrates intake | - | - | - | - | 1件: 257 257 |
193 | CARBOLITHIUM | - | - | - | - | 1件: 2 2 |
194 | CARBOLITHIUM*100CPS 150MG | - | - | - | - | 1件: 2 2 |
195 | Carbomer | 1件: Carbomer Carbomer | - | - | - | 1件: 53 53 |
196 | Carbomer 974P | 2件: Carbomer Carbomer, Carbopol 974P | - | - | - | 1件: 53 53 |
197 | Carbon | 1件: Activated charcoal Activated charcoal | - | - | - | 9件: 6 6, 46, 50, 51, 85, 86, 96, 97, 298 |
198 | Carbon dioxide | 2件: Activated charcoal Activated charcoal, Carbon dioxide | 1件: D00004
D00004
| - | - | 3件: 50 50, 51, 97 |
199 | Carbon Fiber Ankle Foot Orthosis (AFO) | 1件: Activated charcoal Activated charcoal | - | - | - | 1件: 6 6 |
200 | Carbon Modular Radial Head | 1件: Activated charcoal Activated charcoal | - | - | - | 1件: 46 46 |
201 | Carbon Modular Radial Head replacement | 1件: Activated charcoal Activated charcoal | - | - | - | 1件: 46 46 |
202 | Carbon monoxide | 2件: Activated charcoal Activated charcoal, Carbon monoxide | 1件: D09706
D09706
| - | - | 3件: 85 85, 86, 298 |
203 | Carbon-14 BIA 28-6156 | 2件: Activated charcoal Activated charcoal, BIA | - | - | - | 1件: 6 6 |
204 | Carbonate | 1件: Carbonate ion Carbonate ion | - | - | - | 12件: 2 2, 13, 17, 18, 19, 46, 53, 75, 96, 127, 235, 299 |
205 | Carbonate de lithium | 1件: Carbonate ion Carbonate ion | - | - | - | 1件: 2 2 |
206 | Carboplatin | 1件: Carboplatin Carboplatin | 1件: D01363
D01363
| - | - | 4件: 28 28, 34, 60, 85 |
207 | Carboxymethylcellulose | 1件: Carboxymethylcellulose Carboxymethylcellulose | 1件: D07622
D07622
| - | - | 2件: 35 35, 162 |
208 | Carboxymethylcellulose with ionic silver (Aquacel Ag) | 2件: Carboxymethylcellulose Carboxymethylcellulose, Silver | 1件: D07622
D07622
| - | - | 2件: 35 35, 162 |
209 | Cardiac monitoring | - | - | - | - | 1件: 6 6 |
210 | Cardiac MRI | - | - | - | - | 1件: 215 215 |
211 | Cardicor | - | - | - | - | 1件: 113 113 |
212 | Cardicor (Merck brand) | - | - | - | - | 1件: 113 113 |
213 | Cardiovascular profile | - | - | - | - | 1件: 113 113 |
214 | CARDURA | 1件: Doxazosin Doxazosin | 2件: D00608
D00608
,
D07874
| 3件: ADRA1A ADRA1A, ADRA1B, ADRA1D 💬 | 7件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 67 67 |
215 | Care as usual | - | - | - | - | 1件: 15 15 |
216 | Carfilzomib | 1件: Carfilzomib Carfilzomib | 1件: D08880
D08880
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 |
217 | Carglumic Acid | 1件: Carglumic acid Carglumic acid | 1件: D07130
D07130
| 1件: CPS1 CPS1 💬 | 6件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Arginine biosynthesis, Biosynthesis of amino acids, Carbon metabolism, Metabolic pathways, Nitrogen metabolism 💬 | 3件: 245 245, 246, 251 |
218 | Carglumic Acid (Carbaglu®) | 1件: Carglumic acid Carglumic acid | 1件: D07130
D07130
| 1件: CPS1 CPS1 💬 | 6件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Arginine biosynthesis, Biosynthesis of amino acids, Carbon metabolism, Metabolic pathways, Nitrogen metabolism 💬 | 2件: 245 245, 246 |
219 | Carisbamate | 1件: Carisbamate Carisbamate | 1件: D06573
D06573
| - | - | 1件: 144 144 |
220 | Carmustine | 1件: Carmustine Carmustine | 1件: D00254
D00254
| - | - | 5件: 11 11, 13, 14, 28, 60 |
221 | Carmustine, etoposide, cytarabine, and melphalan (BEAM) | 4件: Carmustine Carmustine, Cytarabine, Etoposide, Melphalan | 7件: D00125
D00125
,
D00168
,
D00254
,
D00369
,
D03046
,
D03637
,
D04107
| 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 1件: 13 13 |
222 | Carnitine | 1件: Levocarnitine Levocarnitine | 3件: D02030
D02030
,
D02176
,
D04713
| - | - | 9件: 5 5, 13, 58, 86, 96, 97, 265, 298, 316 |
223 | Carnosine | 1件: Carnosine Carnosine | - | - | - | 2件: 6 6, 13 |
224 | Carnosine supplementation | 1件: Carnosine Carnosine | - | - | - | 1件: 6 6 |
225 | Carnosine, capsulle, 2 g/day, 8 weeks | 1件: Carnosine Carnosine | - | - | - | 1件: 13 13 |
226 | Carotid ultrasound | - | - | - | - | 1件: 78 78 |
227 | Carrageenan | - | - | - | - | 1件: 97 97 |
228 | Carvedilol | 1件: Carvedilol Carvedilol | 2件: D00255
D00255
,
D03415
| 5件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2 💬 | 13件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 5件: 6 6, 57, 86, 113, 210 |
229 | CARVI EXTRACTUM FLUIDUM | - | - | - | - | 1件: 97 97 |
230 | CAS # in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) | - | - | - | - | 1件: 254 254 |
231 | CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4- (trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4- (trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one | - | - | - | - | 1件: 58 58 |
232 | CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one | - | - | - | - | 1件: 58 58 |
233 | CAS No.: 7758-16-9 | - | - | - | - | 1件: 166 166 |
234 | CAS# in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) | - | - | - | - | 1件: 254 254 |
235 | Casein | 1件: Casein Casein | - | - | - | 1件: 97 97 |
236 | Casein glycomacropeptide (CGMP) | 1件: Casein Casein | - | - | - | 1件: 97 97 |
237 | CASIMERSEN | 1件: Casimersen Casimersen | 1件: D11988
D11988
| 1件: DMD DMD 💬 | 4件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Viral myocarditis 💬 | 1件: 113 113 |
238 | Caspofungin | 1件: Caspofungin Caspofungin | 2件: D02501
D02501
,
D07626
| - | - | 1件: 60 60 |
239 | CASPOFUNGIN ACETATE | 2件: Acetate Acetate, Caspofungin | 2件: D02501
D02501
,
D07626
| - | - | 1件: 60 60 |
240 | CAT-1004 | - | - | - | - | 1件: 113 113 |
241 | CAT-354 | - | - | - | - | 1件: 97 97 |
242 | Catapres ampoules | 1件: Clonidine Clonidine | 2件: D00281
D00281
,
D00604
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
243 | Catapresan | - | - | - | - | 2件: 65 65, 78 |
244 | Catapresan 75 | - | - | - | - | 1件: 78 78 |
245 | Catapresan 75, Tabletten | - | - | - | - | 1件: 65 65 |
246 | Catapressan | - | - | - | - | 1件: 6 6 |
247 | Cathepsin S | - | - | - | - | 1件: 53 53 |
248 | Cathepsin S Inhibitor | - | - | - | - | 1件: 53 53 |
249 | Catheter directed therapy | - | - | - | - | 1件: 88 88 |
250 | Catridecacog | 1件: Catridecacog Catridecacog | 1件: D10532
D10532
| - | - | 2件: 97 97, 288 |
251 | Caudal epidural injection | - | - | - | - | 1件: 70 70 |
252 | Caudal Epidural Injection with Celestone | - | - | - | - | 1件: 70 70 |
253 | Caudal Epidural Injection with DepoMedrol | - | - | - | - | 1件: 70 70 |
254 | Caudal Epidural Injection with generic Celestone | - | - | - | - | 1件: 70 70 |
255 | Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) | - | - | - | - | 1件: 85 85 |
256 | Cavosonstat | 1件: Cavosonstat Cavosonstat | 1件: D10916
D10916
| - | - | 1件: 299 299 |
257 | Cayston | 1件: Aztreonam Aztreonam | 2件: D00240
D00240
,
D06558
| - | - | 1件: 299 299 |
258 | Cayston 75 mg Pulver und Lösungsmittel zur Herstellung einer Lösung für einen Vernebler | 1件: Aztreonam Aztreonam | 2件: D00240
D00240
,
D06558
| - | - | 1件: 299 299 |
259 | CAYSTON aztreonam 75 mg powder and solvent for nebuliser solution | 1件: Aztreonam Aztreonam | 2件: D00240
D00240
,
D06558
| - | - | 1件: 299 299 |
260 | CB-01-02 | - | - | - | - | 1件: 97 97 |
261 | CB-01-05-MMX | - | - | - | - | 1件: 97 97 |
262 | CB-280 | - | - | - | - | 1件: 299 299 |
263 | CBD | - | - | - | - | 12件: 2 2, 6, 8, 13, 36, 46, 140, 144, 145, 156, 158, 206 |
264 | CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA. | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 2件: 140 140, 144 |
265 | CBD - Oral Solution, is known as Epidyolex 100 mg/ml oral solution, | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 158 158 |
266 | CBD - Oral Solution, is known as Epidyolex, and is the approved name | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 156 156 |
267 | CBD - Solution Orale, conosciuto come Epidiolex, questo è il nome approvato negli Stati Uniti | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 156 156 |
268 | CBD Oral solution, is known as Epidyolex and is the approved name in the EU | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 156 156 |
269 | CBD soluzione orale nota come Epidyolex e con tale nome è stato approvato in UE | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 156 156 |
270 | CBD-Oral Solution, is known as Epidiolex, and is the approved name in the USA. | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 158 158 |
271 | CBDCA | 1件: Carboplatin Carboplatin | 1件: D01363
D01363
| - | - | 1件: 85 85 |
272 | CBDV | 1件: Cannabidivarin Cannabidivarin | - | - | - | 1件: 193 193 |
273 | CBDV Compound | 1件: Cannabidivarin Cannabidivarin | - | - | - | 1件: 193 193 |
274 | CBN | - | - | - | - | 1件: 36 36 |
275 | CBP-307 | - | - | - | - | 1件: 97 97 |
276 | CC | - | - | - | - | 14件: 13 13, 28, 46, 49, 51, 56, 84, 85, 96, 97, 98, 162, 202, 271 |
277 | CC-100004 | - | - | - | - | 1件: 84 84 |
278 | CC-10004 | - | - | - | - | 5件: 46 46, 56, 97, 162, 271 |
279 | CC-220 | 1件: CC-220 CC-220 | - | - | - | 2件: 49 49, 84 |
280 | CC-220 0.3 mg Daily | 1件: CC-220 CC-220 | - | - | - | 1件: 84 84 |
281 | CC-220 0.6mg Daily | 1件: CC-220 CC-220 | - | - | - | 1件: 84 84 |
282 | CC-292 | - | - | - | - | 1件: 46 46 |
283 | CC-4047 | - | - | - | - | 2件: 28 28, 51 |
284 | CC-5013 | - | - | - | - | 2件: 28 28, 96 |
285 | CC-90001 | - | - | - | - | 1件: 85 85 |
286 | CC-930 | - | - | - | - | 1件: 85 85 |
287 | CC-93538 | - | - | - | - | 1件: 98 98 |
288 | CC-99677 | - | - | - | - | 1件: 271 271 |
289 | CC-99677 30mg Capsule | - | - | - | - | 1件: 271 271 |
290 | CC-99677 60mg Capsule | - | - | - | - | 1件: 271 271 |
291 | CC100 | - | - | - | - | 1件: 2 2 |
292 | CCD 1042 | - | - | - | - | 1件: 152 152 |
293 | CCD 1042, MD 9150000, Mepalon 1042, SPT316 | - | - | - | - | 2件: 152 152, 206 |
294 | CCD 1042, MD 9150000, Mepalon 1042, SPT3162 | - | - | - | - | 1件: 152 152 |
295 | CCI-779 | - | - | - | - | 2件: 13 13, 46 |
296 | CCP-020 | - | - | - | - | 1件: 36 36 |
297 | CCP-690-550-10 | - | - | - | - | 1件: 107 107 |
298 | CCR1 Antagonist | - | - | - | - | 1件: 46 46 |
299 | CCX 354 | - | - | - | - | 1件: 46 46 |
300 | CCX 354-C | - | - | - | - | 1件: 46 46 |
301 | CCX-354 | 1件: CCX-354 CCX-354 | - | - | - | 1件: 46 46 |
302 | CCX-354-C | 1件: CCX-354 CCX-354 | - | - | - | 1件: 46 46 |
303 | CCX140 | - | - | - | - | 1件: 222 222 |
304 | CCX140-B | - | - | - | - | 1件: 222 222 |
305 | CCX168 | - | - | - | - | 5件: 43 43, 44, 66, 109, 222 |
306 | CCX282-B | - | - | - | - | 1件: 96 96 |
307 | CCX354 | - | - | - | - | 1件: 46 46 |
308 | CCX354-C | - | - | - | - | 1件: 46 46 |
309 | CD | - | - | - | - | 7件: 6 6, 13, 46, 51, 96, 97, 265 |
310 | CD-4 guided therapy interruption | - | - | - | - | 1件: 265 265 |
311 | CD-C-Food | - | - | - | - | 1件: 96 96 |
312 | CD-LD CR | - | - | - | - | 1件: 6 6 |
313 | CD-LD IR | - | - | - | - | 1件: 6 6 |
314 | CD19-directed humanised afucosylated monoclonal antibody | - | - | - | - | 1件: 11 11 |
315 | CD19/BCMA CAR T-cells | - | - | - | - | 2件: 16 16, 61 |
316 | CD3-depleted hematopoietic cell transplantation | - | - | - | - | 1件: 60 60 |
317 | CD3/CD19 depleted leukocytes | - | - | - | - | 1件: 284 284 |
318 | CD3/CD19 neg allogeneic BMT | - | - | - | - | 1件: 65 65 |
319 | CD3/CD19 negative allogeneic hematopoietic stem cells | - | - | - | - | 1件: 65 65 |
320 | CD3/CD19 negative hematopoietic stem cells | - | - | - | - | 1件: 85 85 |
321 | CD34 selected autologous hematopoietic cells | - | - | - | - | 1件: 51 51 |
322 | CD34 selected haploidentical PBSCT | - | - | - | - | 1件: 285 285 |
323 | CD34 Stem Cell Selection Therapy | - | - | - | - | 3件: 60 60, 65, 284 |
324 | CD34+ | - | - | - | - | 1件: 65 65 |
325 | CD34+ bone marrow stem cells intravitreal | - | - | - | - | 1件: 90 90 |
326 | CD34+ CELLS | - | - | - | - | 1件: 285 285 |
327 | CD34+ cells transduced with ADA retrovir | - | - | - | - | 1件: 65 65 |
328 | CD34+ enriched, T Cell Depleted donor stem cell product | - | - | - | - | 1件: 326 326 |
329 | CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1a-h?c-OPT | - | - | - | - | 1件: 65 65 |
330 | CD34+ Peripheral Blood Stem Cell Reinfusion | - | - | - | - | 1件: 49 49 |
331 | CD34+ selected cells | - | - | - | - | 1件: 285 285 |
332 | CD34+CELLS | - | - | - | - | 2件: 65 65, 285 |
333 | CD34+SC | - | - | - | - | 1件: 51 51 |
334 | CD3±CD19 depleted hematopoietic stem cell transplantation | - | - | - | - | 1件: 60 60 |
335 | CD45RA depleted leukocytes | - | - | - | - | 1件: 284 284 |
336 | CD45RA-depleted DLI | - | - | - | - | 1件: 60 60 |
337 | CD62L- Tem | - | - | - | - | 1件: 60 60 |
338 | CD7 CAR T-cells | - | - | - | - | 3件: 50 50, 96, 97 |
339 | CDCA | 1件: Chenodeoxycholic acid Chenodeoxycholic acid | 1件: D00163
D00163
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 263 263 |
340 | CDCA Weight-Based Dose TID | 1件: Chenodeoxycholic acid Chenodeoxycholic acid | 1件: D00163
D00163
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 263 263 |
341 | CDMARD | - | - | - | - | 1件: 46 46 |
342 | CDNF | - | - | - | - | 1件: 6 6 |
343 | CDP | - | - | - | - | 1件: 46 46 |
344 | CDP 6038 SC | - | - | - | - | 1件: 46 46 |
345 | CDP3194 | - | - | - | - | 1件: 49 49 |
346 | CDP323 | 1件: CDP323 CDP323 | - | - | - | 1件: 13 13 |
347 | CDP6038 | - | - | - | - | 2件: 46 46, 96 |
348 | CDP7657 | - | - | - | - | 1件: 49 49 |
349 | CDP870 | - | - | - | - | 3件: 46 46, 96, 271 |
350 | CDP870 100mg | - | - | - | - | 1件: 46 46 |
351 | CDP870 200mg | - | - | - | - | 1件: 46 46 |
352 | CDP870 400mg | - | - | - | - | 1件: 46 46 |
353 | CDP870 Fab'-PEG | - | - | - | - | 1件: 46 46 |
354 | CDX | - | - | - | - | 2件: 222 222, 240 |
355 | CDX 6114 | - | - | - | - | 1件: 240 240 |
356 | CDX-1135 | - | - | - | - | 1件: 222 222 |
357 | CDZ173 | - | - | - | - | 2件: 53 53, 65 |
358 | CE 224,535 | - | - | - | - | 1件: 46 46 |
359 | CE-224,535 | - | - | - | - | 1件: 46 46 |
360 | CEBION 500*20CPR MAST 500MG | - | - | - | - | 1件: 10 10 |
361 | CEBION 500MG 20CPR MAST.ARAN | - | - | - | - | 1件: 10 10 |
362 | Cediranib | 1件: Cediranib Cediranib | 1件: D08881
D08881
| 3件: FLT1 FLT1, FLT4, KDR 💬 | 15件: Breast cancer Breast cancer, Calcium signaling pathway, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, MAPK signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Rheumatoid arthritis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 34 34 |
363 | Cediranib Maleate | 1件: Cediranib Cediranib | 1件: D08881
D08881
| 3件: FLT1 FLT1, FLT4, KDR 💬 | 15件: Breast cancer Breast cancer, Calcium signaling pathway, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, MAPK signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Rheumatoid arthritis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 34 34 |
364 | CEFALEXIN | 1件: Cephalexin Cephalexin | 2件: D00263
D00263
,
D00906
| - | - | 1件: 299 299 |
365 | Cefazolin | 1件: Cefazolin Cefazolin | 1件: D02299
D02299
| - | - | 1件: 291 291 |
366 | Cefepime | 1件: Cefepime Cefepime | 1件: D02376
D02376
| - | - | 2件: 60 60, 299 |
367 | CEFEPIME DIHYDROCHLORIDE MONOHYDRATE | 1件: Cefepime Cefepime | 1件: D02376
D02376
| - | - | 1件: 60 60 |
368 | Cefoperazone | 1件: Cefoperazone Cefoperazone | 1件: D07645
D07645
| - | - | 1件: 296 296 |
369 | Ceftaroline | 1件: Ceftaroline fosamil Ceftaroline fosamil | 1件: D08884
D08884
| - | - | 1件: 299 299 |
370 | Ceftazidim | 1件: Ceftazidime Ceftazidime | 2件: D00921
D00921
,
D07654
| - | - | 1件: 299 299 |
371 | Ceftazidim Fresenius Kabi | 1件: Ceftazidime Ceftazidime | 2件: D00921
D00921
,
D07654
| - | - | 1件: 299 299 |
372 | Ceftazidim Fresenius Kabi 2000 mg poeder voor oplossing voor injectie of infusie | 1件: Ceftazidime Ceftazidime | 2件: D00921
D00921
,
D07654
| - | - | 1件: 299 299 |
373 | Ceftazidima | 1件: Ceftazidime Ceftazidime | 2件: D00921
D00921
,
D07654
| - | - | 1件: 299 299 |
374 | CEFTAZIDIMA PENTAIDRATO | 1件: Ceftazidime Ceftazidime | 2件: D00921
D00921
,
D07654
| - | - | 1件: 299 299 |
375 | CEFTAZIDIME | 1件: Ceftazidime Ceftazidime | 2件: D00921
D00921
,
D07654
| - | - | 1件: 299 299 |
376 | Ceftazidime and tobramycin | 2件: Ceftazidime Ceftazidime, Tobramycin | 4件: D00063
D00063
,
D00921
,
D02542
,
D07654
| - | - | 1件: 299 299 |
377 | CEFTAZIDIME PENTAHYDRATE | 1件: Ceftazidime Ceftazidime | 2件: D00921
D00921
,
D07654
| - | - | 1件: 299 299 |
378 | Ceftazidime/avibactam | 2件: Avibactam Avibactam, Ceftazidime | 2件: D00921
D00921
,
D07654
| - | - | 1件: 299 299 |
379 | Ceftolozane | 1件: Ceftolozane Ceftolozane | 1件: D10097
D10097
| - | - | 1件: 299 299 |
380 | Ceftolozane/Tazobactam | 2件: Ceftolozane Ceftolozane, Tazobactam | 2件: D00660
D00660
,
D10097
| - | - | 1件: 299 299 |
381 | Ceftriaxone | 1件: Ceftriaxone Ceftriaxone | 2件: D00924
D00924
,
D07659
| - | - | 3件: 2 2, 6, 97 |
382 | Cefuroxim | 1件: Cefuroxime Cefuroxime | 4件: D00262
D00262
,
D00914
,
D00915
,
D03431
| - | - | 1件: 299 299 |
383 | Cefuroxime | 1件: Cefuroxime Cefuroxime | 4件: D00262
D00262
,
D00914
,
D00915
,
D03431
| - | - | 2件: 97 97, 299 |
384 | CELBESTA® | - | - | - | - | 1件: 46 46 |
385 | Celebra | - | - | - | - | 1件: 46 46 |
386 | Celebra (celecoxib) | 1件: Celecoxib Celecoxib | 1件: D00567
D00567
| 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 |
387 | CELEBREX | 1件: Celecoxib Celecoxib | 1件: D00567
D00567
| 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 4件: 46 46, 96, 107, 271 |
388 | Celebrex 200 mg | - | - | - | - | 1件: 46 46 |
389 | Celebrex 200 mg capsule, hard | 1件: Celecoxib Celecoxib | 1件: D00567
D00567
| 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 |
390 | Celebrex 200 mg Hartkapseln | 1件: Celecoxib Celecoxib | 1件: D00567
D00567
| 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 |
391 | CELEBREX 200MG 20CPS | 1件: Celecoxib Celecoxib | 1件: D00567
D00567
| 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 |
392 | Celebrex 200Mg Capsule | - | - | - | - | 1件: 70 70 |
393 | CELEBREX® | - | - | - | - | 1件: 46 46 |
394 | Celecoxib | 1件: Celecoxib Celecoxib | 1件: D00567
D00567
| 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 10件: 2 2, 3, 34, 46, 70, 89, 107, 161, 171, 271 |
395 | Celecoxib (Celebrex) | 1件: Celecoxib Celecoxib | 1件: D00567
D00567
| 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 34 34 |
396 | Celecoxib 200 milligrams | 1件: Celecoxib Celecoxib | 1件: D00567
D00567
| 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 |
397 | Celecoxib 200mg capsule | 1件: Celecoxib Celecoxib | 1件: D00567
D00567
| 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 |
398 | Celecoxib 400 milligrams | 1件: Celecoxib Celecoxib | 1件: D00567
D00567
| 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 |
399 | Celecoxib, Celebrex® | 1件: Celecoxib Celecoxib | 1件: D00567
D00567
| 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 |
400 | Celiac Block with triamcinolone and bupivicaine | 1件: Triamcinolone Triamcinolone | 5件: D00385
D00385
,
D00983
,
D00984
,
D00985
,
D06216
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 298 298 |
401 | Celiprolol | 1件: Celiprolol Celiprolol | 1件: D07660
D07660
| 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 168 168 |
402 | Cell processing for TCRabeta+/CD19+ depletion | - | - | - | - | 1件: 65 65 |
403 | Cell processing for TCRaß+/CD19+ depletion | - | - | - | - | 1件: 65 65 |
404 | Cell transplantation | - | - | - | - | 1件: 36 36 |
405 | Cell-based therapeutics | - | - | - | - | 1件: 2 2 |
406 | Cell-based therapy | - | - | - | - | 1件: 2 2 |
407 | Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients | - | - | - | - | 1件: 2 2 |
408 | Cellavita HD Higher dose | - | - | - | - | 1件: 8 8 |
409 | Cellavita HD Lower Dose | - | - | - | - | 1件: 8 8 |
410 | Cellavita-HD | - | - | - | - | 1件: 8 8 |
411 | CELLCEPT | - | - | - | - | 5件: 11 11, 13, 42, 43, 49 |
412 | CellCept (Mycophenolate Mofetil) | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 4件: D00752
D00752
,
D05094
,
D05095
,
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 2件: 42 42, 43 |
413 | CellCept 500 mg | - | - | - | - | 1件: 11 11 |
414 | CellCept 500 mg comprimidos recubiertos | - | - | - | - | 1件: 35 35 |
415 | CellCept 500 mg film-coated tablets | 1件: Mycophenolate mofetil Mycophenolate mofetil | 3件: D00752
D00752
,
D05094
,
D05095
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 1件: 11 11 |
416 | CellCept 500 mg tablets | 1件: Mycophenolate mofetil Mycophenolate mofetil | 3件: D00752
D00752
,
D05094
,
D05095
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 1件: 11 11 |
417 | CELLCEPT® | 1件: Mycophenolate mofetil Mycophenolate mofetil | 3件: D00752
D00752
,
D05094
,
D05095
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 1件: 35 35 |
418 | Cellcept® in autoimmune bullous dermatoses | - | - | - | - | 2件: 35 35, 162 |
419 | CellCept®500 mg comprimidos | - | - | - | - | 1件: 35 35 |
420 | CellCept®500 mg tablets | 1件: Mycophenolate mofetil Mycophenolate mofetil | 3件: D00752
D00752
,
D05094
,
D05095
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 1件: 11 11 |
421 | Cellular therapy with EBV specific autologous CTL infusion | - | - | - | - | 1件: 13 13 |
422 | Cellule CD34+ autologhe trasdotte con IDUA LV codificante per il cDNA dell'alfa-L-iduronidasi | - | - | - | - | 1件: 19 19 |
423 | Cellulose | 1件: Microcrystalline cellulose Microcrystalline cellulose | 1件: D00093
D00093
| - | - | 4件: 35 35, 53, 96, 162 |
424 | Cellulose acetate with petrolatum | 3件: Acetate Acetate, Microcrystalline cellulose, Petrolatum | 2件: D00093
D00093
,
D05331
| - | - | 2件: 35 35, 162 |
425 | Cellvizio 100 Series System with Confocal Miniprobes | - | - | - | - | 1件: 215 215 |
426 | Celulas hepatocitos troncales adultas alogenicas de higado expandidas | - | - | - | - | 1件: 251 251 |
427 | Celulas madre mesenquimales troncales adultas alogenicas de médula ósea no expandida | - | - | - | - | 1件: 274 274 |
428 | Cemdisiran | 1件: Cemdisiran Cemdisiran | - | - | - | 4件: 11 11, 62, 66, 109 |
429 | Cendakimab | - | - | - | - | 1件: 98 98 |
430 | Cenegermin | 1件: Cenegermin Cenegermin | 1件: D11028
D11028
| 1件: NGFR NGFR 💬 | 8件: Apoptosis - multiple species Apoptosis - multiple species, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Transcriptional misregulation in cancer 💬 | 1件: 53 53 |
431 | Cenerimod | 1件: Cenerimod Cenerimod | 1件: D11283
D11283
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 49 49 |
432 | Cenerimod 0.5 mg | 1件: Cenerimod Cenerimod | 1件: D11283
D11283
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 49 49 |
433 | Cenerimod 1 mg | 1件: Cenerimod Cenerimod | 1件: D11283
D11283
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 49 49 |
434 | Cenerimod 2 mg | 1件: Cenerimod Cenerimod | 1件: D11283
D11283
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 49 49 |
435 | Cenerimod 4 mg | 1件: Cenerimod Cenerimod | 1件: D11283
D11283
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 49 49 |
436 | Cenicriviroc | 1件: Cenicriviroc Cenicriviroc | 1件: D09878
D09878
| 2件: CCR2 CCR2, CCR5 💬 | 9件: Chemokine signaling pathway Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Toxoplasmosis, Viral carcinogenesis, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 94 94 |
437 | Cenicriviroc 150 mg | 1件: Cenicriviroc Cenicriviroc | 1件: D09878
D09878
| 2件: CCR2 CCR2, CCR5 💬 | 9件: Chemokine signaling pathway Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Toxoplasmosis, Viral carcinogenesis, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 94 94 |
438 | CENSAVUDINE | 1件: Censavudine Censavudine | 1件: D10550
D10550
| - | - | 2件: 2 2, 127 |
439 | Centricyte 1000 | - | - | - | - | 2件: 85 85, 229 |
440 | CEP-1347 | 1件: CEP-1347 CEP-1347 | - | - | - | 1件: 6 6 |
441 | CEP-1347 10mg | 1件: CEP-1347 CEP-1347 | - | - | - | 1件: 6 6 |
442 | CEP-1347 50mg | 1件: CEP-1347 CEP-1347 | - | - | - | 1件: 6 6 |
443 | CEP-33457 | - | - | - | - | 1件: 49 49 |
444 | CEP1347 | - | - | - | - | 1件: 6 6 |
445 | CEP1347 25mg | - | - | - | - | 1件: 6 6 |
446 | Cephalexin | 1件: Cephalexin Cephalexin | 2件: D00263
D00263
,
D00906
| - | - | 1件: 299 299 |
447 | CER-001 | - | - | - | - | 1件: 79 79 |
448 | Ceralifimod | 1件: Ceralifimod Ceralifimod | - | - | - | 1件: 13 13 |
449 | Ceralifmod | - | - | - | - | 1件: 13 13 |
450 | Ceramic on Ceramic articulation | - | - | - | - | 1件: 46 46 |
451 | Ceramic on Polyethylene articulation | - | - | - | - | 1件: 46 46 |
452 | Cerazette | - | - | - | - | 1件: 230 230 |
453 | CERC-006 | - | - | - | - | 1件: 278 278 |
454 | Cerdelga | 1件: Eliglustat Eliglustat | 1件: D09893
D09893
| 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 |
455 | CERE-120 | - | - | - | - | 1件: 6 6 |
456 | CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) | - | - | - | - | 1件: 6 6 |
457 | CERE-120: Adeno-Associated Virus Delivery of Neurturin | - | - | - | - | 1件: 6 6 |
458 | Cerebral Dopamine Neurotrophic Factor | 1件: Dopamine Dopamine | 2件: D00633
D00633
,
D07870
| 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
459 | Cerebro-spinal fluid | - | - | - | - | 1件: 13 13 |
460 | Ceredase | 1件: Alglucerase Alglucerase | 1件: D02810
D02810
| 1件: GBA GBA 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 |
461 | CEREDASE™ | 1件: Alglucerase Alglucerase | 1件: D02810
D02810
| 1件: GBA GBA 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 |
462 | Ceretec | 1件: Technetium Tc-99m exametazime Technetium Tc-99m exametazime | - | - | - | 1件: 6 6 |
463 | CERETEC (TM) Estabilizado | 1件: Technetium Tc-99m exametazime Technetium Tc-99m exametazime | - | - | - | 1件: 6 6 |
464 | CEREZYME | 1件: Imiglucerase Imiglucerase | 1件: D03020
D03020
| 1件: GBA GBA 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 |
465 | Cerezyme (imiglucerase for injection) | 1件: Imiglucerase Imiglucerase | 1件: D03020
D03020
| 1件: GBA GBA 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 |
466 | Cerezyme 400 Units Powder for concentrate for solution for infusion | 1件: Imiglucerase Imiglucerase | 1件: D03020
D03020
| 1件: GBA GBA 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 |
467 | Cerezyme® | 1件: Imiglucerase Imiglucerase | 1件: D03020
D03020
| 1件: GBA GBA 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 |
468 | Cerezyme® / Imiglucerase | 1件: Imiglucerase Imiglucerase | 1件: D03020
D03020
| 1件: GBA GBA 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 |
469 | Cerliponase Alfa | 1件: Cerliponase alfa Cerliponase alfa | 1件: D10813
D10813
| 1件: TPP1 TPP1 💬 | 1件: Lysosome Lysosome 💬 | 1件: 19 19 |
470 | Certican | 1件: Everolimus Everolimus | 1件: D02714
D02714
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 4件: 67 67, 96, 158, 228 |
471 | Certican 0,5 | 1件: Everolimus Everolimus | 1件: D02714
D02714
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 |
472 | Certican 0,5 mg Tabletten | 1件: Everolimus Everolimus | 1件: D02714
D02714
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 |
473 | Certican 0,75mg | 1件: Everolimus Everolimus | 1件: D02714
D02714
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 |
474 | Certican 0,75mg Tabletten | 1件: Everolimus Everolimus | 1件: D02714
D02714
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 |
475 | Certican 1 mg tablets | 1件: Everolimus Everolimus | 1件: D02714
D02714
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 |
476 | Certican Tabletten | 1件: Everolimus Everolimus | 1件: D02714
D02714
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 67 67 |
477 | Certolizumab | - | - | - | - | 5件: 46 46, 49, 96, 270, 271 |
478 | Certolizumab Pegol | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 8件: 37 37, 46, 49, 96, 97, 107, 226, 271 |
479 | Certolizumab pegol (CDP870) | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 96 |
480 | Certolizumab pegol (CDP870, CZP) | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 |
481 | Certolizumab pegol (CDP870, tradename Cimzia) | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
482 | Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg) | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
483 | Certolizumab Pegol (CZP) | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 46 46, 96, 107, 271 |
484 | Certolizumab Pegol (CZP) 200 mg | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
485 | Certolizumab Pegol (CZP) 400 mg | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
486 | Certolizumab pegol (rINN) | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 |
487 | Certolizumab Pegol + Methotrexate (MTX) | 2件: Certolizumab pegol Certolizumab pegol, Methotrexate | 3件: D00142
D00142
,
D02115
,
D03441
| 3件: DHFR DHFR, DHFR2, TNF 💬 | 71件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Folate biosynthesis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Metabolic pathways, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, One carbon pool by folate, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
488 | Certolizumab pegol / CIMZIA | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 |
489 | Certolizumab Pegol /Cimzia | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 |
490 | Certolizumab Pegol 200 MG/ML [Cimzia] | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
491 | Certolizumab pegol 400 mg | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 |
492 | CERTOLUZIMAB PEGOL | - | - | - | - | 1件: 46 46 |
493 | Cervarix | 1件: Human papillomavirus type 16 L1 capsid protein antigen Human papillomavirus type 16 L1 capsid protein antigen | - | - | - | 3件: 49 49, 50, 107 |
494 | Cervarix suspensie voor injectie | 1件: Human papillomavirus type 16 L1 capsid protein antigen Human papillomavirus type 16 L1 capsid protein antigen | - | - | - | 3件: 49 49, 50, 107 |
495 | Cervical Orthosis (CO) | - | - | - | - | 1件: 70 70 |
496 | Cesamet™ (nabilone) | 1件: Nabilone Nabilone | 1件: D05099
D05099
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
497 | Ceterizine | - | - | - | - | 1件: 13 13 |
498 | Cetirizina | 1件: Cetirizine Cetirizine | 2件: D00664
D00664
,
D07662
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 3件: 13 13, 28, 300 |
499 | CETIRIZINA DICLORIDRATO | 1件: Cetirizine Cetirizine | 2件: D00664
D00664
,
D07662
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 28 28 |
500 | Cetirizina Mylan Generics | 1件: Cetirizine Cetirizine | 2件: D00664
D00664
,
D07662
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
501 | CETIRIZINA SANDOZ - 10 MG COMPRESSE RIVESTITE CON FILM 20 COMPRESSE IN BLISTER PVC/ALU | 1件: Cetirizine Cetirizine | 2件: D00664
D00664
,
D07662
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 300 300 |
502 | Cetirizine | 1件: Cetirizine Cetirizine | 2件: D00664
D00664
,
D07662
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 2件: 13 13, 35 |
503 | CETIRIZINE HYDROCHLORIDE | 1件: Cetirizine Cetirizine | 2件: D00664
D00664
,
D07662
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
504 | Cetrorelix | 1件: Cetrorelix Cetrorelix | 2件: D01685
D01685
,
D07665
| 1件: GNRHR GNRHR 💬 | 2件: GnRH signaling pathway GnRH signaling pathway, Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 |
505 | Cetuximab | 1件: Cetuximab Cetuximab | 1件: D03455
D03455
| 1件: EGFR EGFR 💬 | 48件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Coronavirus disease - COVID-19, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis 💬 | 5件: 34 34, 51, 86, 89, 331 |
506 | Cevidoplenib | - | - | - | - | 1件: 46 46 |
507 | Cevimeline | 1件: Cevimeline Cevimeline | 2件: D00661
D00661
,
D07667
| 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 1件: 53 53 |
508 | CF patients with a G551D mutation and treated with Ivacaftor | 1件: Ivacaftor Ivacaftor | 1件: D09916
D09916
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
509 | CF101 | - | - | - | - | 1件: 46 46 |
510 | CF101 1 mg | - | - | - | - | 1件: 46 46 |
511 | CF101 2 mg | - | - | - | - | 1件: 46 46 |
512 | CFTR Modulators | - | - | - | - | 1件: 299 299 |
513 | CFTR potentiator | - | - | - | - | 1件: 299 299 |
514 | CFZ533 | - | - | - | - | 4件: 11 11, 46, 49, 53 |
515 | CFZ533 (iscalimab) | 1件: Iscalimab Iscalimab | 1件: D11610
D11610
| 1件: CD40 CD40 💬 | 17件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Intestinal immune network for IgA production, Lipid and atherosclerosis, Malaria, NF-kappa B signaling pathway, Primary immunodeficiency, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Viral myocarditis 💬 | 1件: 53 53 |
516 | CFZ533 active - Cohort 1 | - | - | - | - | 1件: 53 53 |
517 | CFZ533 active - Cohort 2 | - | - | - | - | 1件: 53 53 |
518 | CFZ533 active - Cohort 3 | - | - | - | - | 1件: 53 53 |
519 | CFZ533 active -Cohort 3 | - | - | - | - | 1件: 53 53 |
520 | CGMP protein | - | - | - | - | 1件: 97 97 |
521 | CGP 77116 | - | - | - | - | 1件: 13 13 |
522 | CH-1504 | - | - | - | - | 1件: 46 46 |
523 | CH-4051 | - | - | - | - | 1件: 46 46 |
524 | Ch11-1F4 (NSC-711516) | - | - | - | - | 1件: 28 28 |
525 | ChAdOx1 nCoV-19 | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 3件: 46 46, 51, 299 |
526 | ChAdOx2 HAV | - | - | - | - | 1件: 96 96 |
527 | Champix | 1件: Varenicline Varenicline | 1件: D08669
D08669
| 2件: CHRNA4 CHRNA4, CHRNB2 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction 💬 | 1件: 6 6 |
528 | Change in daily dosage of Growth Hormone | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
529 | Charcoal | - | - | - | - | 1件: 13 13 |
530 | Chelation | - | - | - | - | 1件: 60 60 |
531 | Chemical conjugate of recombinant human growth hormone (rhGH) and human immunoglobulin G4 fragment (HMC001) | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
532 | CHEMICALLY MODIFIED RECOMBINANT HUMAN SULFAMIDASE | - | - | - | - | 1件: 19 19 |
533 | Chemotherapy | - | - | - | - | 3件: 28 28, 60, 285 |
534 | Chemotherapy, intrathecal chemotherapy, steroid therapy | - | - | - | - | 1件: 65 65 |
535 | Chenodeoxycholic acid | 1件: Chenodeoxycholic acid Chenodeoxycholic acid | 1件: D00163
D00163
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 4件: 20 20, 96, 234, 263 |
536 | Chenodiol | 1件: Chenodeoxycholic acid Chenodeoxycholic acid | 1件: D00163
D00163
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 96 96 |
537 | Chenofalk | - | - | - | - | 1件: 96 96 |
538 | CHF 6333 | - | - | - | - | 1件: 299 299 |
539 | CHF6333 (Part 1 - SAD) | - | - | - | - | 1件: 299 299 |
540 | CHF6333 (Part 2 - MAD) | - | - | - | - | 1件: 299 299 |
541 | Chicken | 1件: Chicken Chicken | - | - | - | 1件: 46 46 |
542 | Chicken type II collagen | 1件: Chicken Chicken | - | - | - | 1件: 46 46 |
543 | CHIMERIC FIBRIL-REACTIVE IGG1K MONOCLONAL ANTIBODY 11-1F4 | - | - | - | - | 1件: 28 28 |
544 | Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4 | - | - | - | - | 1件: 28 28 |
545 | Chimeric Human-Murine IgG1 | - | - | - | - | 1件: 46 46 |
546 | Chimeric human/mouse anti-CD-20 monoclonal antibody | - | - | - | - | 1件: 46 46 |
547 | Chimeric IgG1 monoclonal antibody | - | - | - | - | 1件: 96 96 |
548 | Chimeric monoclonal antibody, IgG4 subtype | - | - | - | - | 2件: 43 43, 44 |
549 | Chimeric murine human anti-IL-6 monoclonal antibody | - | - | - | - | 1件: 331 331 |
550 | Chinese Herb Prescription Granule plus prednisone | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 66 66 |
551 | Chinese herbal concoction twice a day for 6 months | - | - | - | - | 1件: 60 60 |
552 | Chinese herbal medicine treatment | - | - | - | - | 1件: 6 6 |
553 | Chinese herbs based on syndrome differentiation | - | - | - | - | 1件: 224 224 |
554 | Chlor | 1件: Chlorine Chlorine | - | - | - | 2件: 46 46, 271 |
555 | Chlorambucil | 1件: Chlorambucil Chlorambucil | 1件: D00266
D00266
| - | - | 1件: 222 222 |
556 | Chlorhexidine | 1件: Chlorhexidine Chlorhexidine | 4件: D00858
D00858
,
D01345
,
D03463
,
D07668
| - | - | 2件: 86 86, 299 |
557 | Chlorhexidine Gluconate | 1件: Chlorhexidine Chlorhexidine | 4件: D00858
D00858
,
D01345
,
D03463
,
D07668
| - | - | 1件: 299 299 |
558 | Chlorhexidine gluconate oral rinse | 1件: Chlorhexidine Chlorhexidine | 4件: D00858
D00858
,
D01345
,
D03463
,
D07668
| - | - | 1件: 299 299 |
559 | Chloride | 1件: Chloride ion Chloride ion | - | - | - | 29件: 6 6, 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 67, 78, 96, 97, 107, 127, 168, 171, 193, 227, 228, 251, 271, 288, 296, 297, 299, 338 |
560 | Chlorogenic Acid | 1件: Chlorogenic Acid Chlorogenic Acid | - | - | - | 1件: 97 97 |
561 | Chloroquine | 1件: Chloroquine Chloroquine | 3件: D02125
D02125
,
D02366
,
D03469
| - | - | 3件: 46 46, 49, 95 |
562 | Chloroquine diphosphate | 1件: Chloroquine Chloroquine | 3件: D02125
D02125
,
D02366
,
D03469
| - | - | 1件: 95 95 |
563 | Chloroquine diphosphate 250mg | 1件: Chloroquine Chloroquine | 3件: D02125
D02125
,
D02366
,
D03469
| - | - | 1件: 95 95 |
564 | Chlorothiazide | 1件: Chlorothiazide Chlorothiazide | 2件: D00519
D00519
,
D03471
| 1件: SLC12A3 SLC12A3 💬 | - | 1件: 225 225 |
565 | Chlorpromazine | 1件: Chlorpromazine Chlorpromazine | 4件: D00270
D00270
,
D00789
,
D03274
,
D04034
| 13件: ADRA2A ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2B, HTR2C 💬 | 22件: Alcoholism Alcoholism, Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Cocaine addiction, Dopaminergic synapse, Gap junction, Gastric acid secretion, Inflammatory mediator regulation of TRP channels, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Rap1 signaling pathway, Regulation of actin cytoskeleton, Salivary secretion, Serotonergic synapse, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 254 254 |
566 | Chlorpromazine Hydrochloride | 1件: Chlorpromazine Chlorpromazine | 4件: D00270
D00270
,
D00789
,
D03274
,
D04034
| 13件: ADRA2A ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2B, HTR2C 💬 | 22件: Alcoholism Alcoholism, Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Cocaine addiction, Dopaminergic synapse, Gap junction, Gastric acid secretion, Inflammatory mediator regulation of TRP channels, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Rap1 signaling pathway, Regulation of actin cytoskeleton, Salivary secretion, Serotonergic synapse, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 254 254 |
567 | CHLORURE DE SODIUM | - | - | - | - | 1件: 96 96 |
568 | Chocolate | 1件: Cocoa Cocoa | - | - | - | 1件: 6 6 |
569 | CHOLECALCIFEROL | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 10件: 13 13, 19, 34, 46, 49, 75, 96, 97, 298, 299 |
570 | Cholecalciferol (Vitamin D3) | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 2件: 13 13, 299 |
571 | Cholecalciferol (vitaminD3) | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 299 299 |
572 | Cholecalciferol 10,000 IU | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 |
573 | Cholecalciferol 15000 UNT/ML Oral Solution | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 75 75 |
574 | Cholecalciferol 400 IU | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 |
575 | Cholecalciferol and C. Xanthorrhiza | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 49 49 |
576 | CHOLECALCIFEROL CONCENTRATE | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 |
577 | CHOLECALCIFEROL CONCENTRATE (WATER-DISPERSIBLE FORM) | 2件: Cholecalciferol Cholecalciferol, Water | 2件: D00001
D00001
,
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 |
578 | Cholecalciferol Pill | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 299 299 |
579 | Cholecalciferol, Vitamin D3 | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 13 13 |
580 | Cholestagel | 1件: Colesevelam Colesevelam | 2件: D03582
D03582
,
D07743
| - | - | 1件: 96 96 |
581 | Cholesterol | 1件: Cholesterol Cholesterol | 1件: D00040
D00040
| - | - | 6件: 19 19, 90, 160, 259, 261, 310 |
582 | Cholesterol supplementation | 1件: Cholesterol Cholesterol | 1件: D00040
D00040
| - | - | 1件: 310 310 |
583 | Cholestyramine | 1件: Cholestyramine Cholestyramine | - | - | - | 2件: 13 13, 79 |
584 | Cholic Acid | 1件: Cholic Acid Cholic Acid | 1件: D10699
D10699
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 4件: 20 20, 234, 265, 310 |
585 | Cholic Acids | - | - | - | - | 2件: 20 20, 234 |
586 | Choline | 1件: Choline Choline | 1件: D07690
D07690
| - | - | 4件: 93 93, 171, 193, 299 |
587 | Choline Chloride | 2件: Chloride ion Chloride ion, Choline | 1件: D07690
D07690
| - | - | 1件: 299 299 |
588 | Choline supplementation | 1件: Choline Choline | 1件: D07690
D07690
| - | - | 1件: 299 299 |
589 | Chondroitin sulfate | 2件: Chondroitin sulfate Chondroitin sulfate, Sulfate ion | - | - | - | 2件: 96 96, 226 |
590 | Chong Kun Dang Tofacitinib Tablet | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
| 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
591 | CHR-1103 / GBR500 | - | - | - | - | 1件: 13 13 |
592 | Chromium | 1件: Chromium Chromium | - | - | - | 1件: 46 46 |
593 | Chronic Antioxidant | - | - | - | - | 1件: 299 299 |
594 | Chronic Corticosteroid Therapy | - | - | - | - | 1件: 113 113 |
595 | Chrono Super PID then Generic Syringe-Gammanorm | - | - | - | - | 1件: 65 65 |
596 | Chronocort | - | - | - | - | 1件: 81 81 |
597 | Chronocort 10mg | - | - | - | - | 1件: 81 81 |
598 | Chronocort 5mg | - | - | - | - | 1件: 81 81 |
599 | Chronocort® | - | - | - | - | 1件: 81 81 |
600 | Chronocort® 10 mg | - | - | - | - | 1件: 81 81 |
601 | Chronocort® 20 mg | - | - | - | - | 1件: 81 81 |
602 | Chronocort® 5 mg | - | - | - | - | 1件: 81 81 |
603 | CHS-0214 | - | - | - | - | 1件: 46 46 |
604 | Chuna manipulation | - | - | - | - | 1件: 70 70 |
605 | Chuna manual medicine | - | - | - | - | 1件: 70 70 |
606 | CHX A-DTPA anti-CD66 antibody | 1件: Pentetic acid Pentetic acid | 1件: D05422
D05422
| - | - | 1件: 28 28 |
607 | CHX-A-DTPA-Anti-CD66 | 1件: Pentetic acid Pentetic acid | 1件: D05422
D05422
| - | - | 1件: 28 28 |
608 | CI-984 | - | - | - | - | 1件: 75 75 |
609 | CI-984, 17AA70, PD 132301-2 | - | - | - | - | 1件: 81 81 |
610 | Cialis | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 |
611 | CIALIS - 20 MG 2 COMPRESSE RIVESTITE CON FILM IN BLISTER USO ORALE | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 75 75 |
612 | Cialis 10 mg film-coated tablets | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 113 |
613 | Cialis 2.5 mg film-coated tablets | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 113 |
614 | CIALIS 20 mg comprimidos recubiertos con película | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
615 | Cialis 20 mg film-coated tablets | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 113 |
616 | Cialis 5 mg film-coated tablets | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 113 |
617 | Cianocobalamina | 1件: Cyanocobalamin Cyanocobalamin | 4件: D00166
D00166
,
D03615
,
D03616
,
D03617
| - | - | 1件: 13 13 |
618 | CIANOCOBALAMINA FU DC.IT | 1件: Cyanocobalamin Cyanocobalamin | 4件: D00166
D00166
,
D03615
,
D03616
,
D03617
| - | - | 1件: 13 13 |
619 | Cibenzoline | 1件: Cibenzoline Cibenzoline | 1件: D03492
D03492
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 58 58 |
620 | CIC using LoFric Primo | - | - | - | - | 1件: 13 13 |
621 | Ciclesonide | 1件: Ciclesonide Ciclesonide | 1件: D01703
D01703
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 84 84 |
622 | Cicletanine | 1件: Cicletanine Cicletanine | 1件: D03487
D03487
| - | - | 1件: 86 86 |
623 | Cicletanine hydrochloride | 1件: Cicletanine Cicletanine | 1件: D03487
D03487
| - | - | 1件: 86 86 |
624 | Ciclofosfamida | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 222 222 |
625 | Ciclofosfamide | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 13 13 |
626 | Ciclosporin | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 13件: 26 26, 46, 49, 50, 53, 55, 60, 61, 97, 222, 226, 228, 269 |
627 | Ciclosporin (Ciclosporinium) | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 |
628 | CICLOSPORIN A | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 |
629 | Ciclosporin Soft Capsule | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 |
630 | CICLOSPORINA | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 4件: 49 49, 60, 97, 228 |
631 | Ciclosporina / Ciclosporin | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 |
632 | Ciclosporina A Liposomica Aerolised Liposomal Ciclosporin A | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 |
633 | Ciclosporina/ Ciclosporin | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 |
634 | Ciclosporine | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 60 60, 228 |
635 | Ciclosporine A | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 |
636 | Ciclosporine, Ciclosporina | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 |
637 | Cidofovir | 1件: Cidofovir Cidofovir | 1件: D00273
D00273
| - | - | 1件: 25 25 |
638 | Ciklosporin | - | - | - | - | 1件: 226 226 |
639 | CILASTATIN | 1件: Cilastatin Cilastatin | 2件: D02194
D02194
,
D07698
| 1件: DPEP1 DPEP1 💬 | - | 1件: 60 60 |
640 | Cilastatine | 1件: Cilastatin Cilastatin | 2件: D02194
D02194
,
D07698
| 1件: DPEP1 DPEP1 💬 | - | 1件: 60 60 |
641 | Cilazapril | 1件: Cilazapril Cilazapril | 2件: D01069
D01069
,
D07699
| 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 1件: 66 66 |
642 | Ciliary neurotrophic factor | 1件: Ciliary neurotrophic factor Ciliary neurotrophic factor | - | - | - | 1件: 90 90 |
643 | Ciliary Neurotrophic Factor Implant NT-501 | 1件: Ciliary neurotrophic factor Ciliary neurotrophic factor | - | - | - | 1件: 90 90 |
644 | Cilnidipine | 1件: Cilnidipine Cilnidipine | 1件: D01173
D01173
| 5件: CACNA1B CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 41件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Huntington disease, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Morphine addiction, Nicotine addiction, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 67 67 |
645 | CILO | - | - | - | - | 1件: 94 94 |
646 | Cilofexor | 1件: Cilofexor Cilofexor | - | - | - | 2件: 93 93, 94 |
647 | CILOSTAZOL | 1件: Cilostazol Cilostazol | 1件: D01896
D01896
| 3件: PDE3A PDE3A, PDE3B, TBXA2R 💬 | 14件: Apelin signaling pathway Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Platelet activation, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 51 51, 70, 124 |
648 | Cimetidine | 1件: Cimetidine Cimetidine | 2件: D00295
D00295
,
D03503
| 1件: HRH2 HRH2 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬 | 2件: 2 2, 254 |
649 | Cimetidine plus Dexpramipexole | 2件: Cimetidine Cimetidine, Dexpramipexole | 3件: D00295
D00295
,
D03503
,
D09886
| 6件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5, HRH2 💬 | 12件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Gastric acid secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 2 2 |
650 | CIMZIA | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 5件: 46 46, 49, 96, 97, 271 |
651 | CIMZIA (Certolizumab Pegol) | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
652 | CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
653 | CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI ALCOOL | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
654 | Cimzia 200 mg injeksjonsvæske, oppløsning | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
655 | Cimzia 200 mg solution for injection | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 46 46, 96, 271 |
656 | CIMZIA certolizumab pegol 200 mg/ml solution for injection | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 |
657 | Cimzia® | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 271 |
658 | Cinacalcet | 1件: Cinacalcet Cinacalcet | 2件: D03504
D03504
,
D03505
| 1件: CASR CASR 💬 | 2件: NOD-like receptor signaling pathway NOD-like receptor signaling pathway, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 238 238 |
659 | CinnaTropin® | - | - | - | - | 1件: 78 78 |
660 | Cinryze | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 2件: 13 13, 61 |
661 | CINRYZE® (C1 esterase inhibitor [human]) | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 61 61 |
662 | Cipaglucosidase Alfa | 1件: Cipaglucosidase alfa Cipaglucosidase alfa | 1件: D11798
D11798
| 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 |
663 | Cipaglucosidase alfa (ATB200) | 1件: Cipaglucosidase alfa Cipaglucosidase alfa | 1件: D11798
D11798
| 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 |
664 | Cipaglucosidasi alfa | - | - | - | - | 1件: 256 256 |
665 | CIPRALEX | - | - | - | - | 1件: 6 6 |
666 | Cipro (Ciprofloxacin, BAYQ3939) | 1件: Ciprofloxacin Ciprofloxacin | 2件: D00186
D00186
,
D02216
| - | - | 1件: 299 299 |
667 | Cipro Inhale | 1件: Ciprofloxacin Ciprofloxacin | 2件: D00186
D00186
,
D02216
| - | - | 1件: 299 299 |
668 | Ciprofloxacin | 1件: Ciprofloxacin Ciprofloxacin | 2件: D00186
D00186
,
D02216
| - | - | 5件: 2 2, 60, 96, 97, 299 |
669 | Ciprofloxacin (BAYQ3939) dry powder for inhalation | 1件: Ciprofloxacin Ciprofloxacin | 2件: D00186
D00186
,
D02216
| - | - | 1件: 299 299 |
670 | Ciprofloxacin (Cipro Inhale, BAYQ3939) | 1件: Ciprofloxacin Ciprofloxacin | 2件: D00186
D00186
,
D02216
| - | - | 1件: 299 299 |
671 | Ciprofloxacin (Cipro, BAYQ3939) | 1件: Ciprofloxacin Ciprofloxacin | 2件: D00186
D00186
,
D02216
| - | - | 1件: 299 299 |
672 | Ciprofloxacin (ciproxin) | 1件: Ciprofloxacin Ciprofloxacin | 2件: D00186
D00186
,
D02216
| - | - | 1件: 299 299 |
673 | Ciprofloxacin dispersion for inhalation | 1件: Ciprofloxacin Ciprofloxacin | 2件: D00186
D00186
,
D02216
| - | - | 1件: 299 299 |
674 | Ciprofloxacin DPI | 1件: Ciprofloxacin Ciprofloxacin | 2件: D00186
D00186
,
D02216
| - | - | 1件: 299 299 |
675 | Ciprofloxacin DPI (BAYQ3939) | 1件: Ciprofloxacin Ciprofloxacin | 2件: D00186
D00186
,
D02216
| - | - | 1件: 299 299 |
676 | Ciprofloxacin for Inhalation | 1件: Ciprofloxacin Ciprofloxacin | 2件: D00186
D00186
,
D02216
| - | - | 1件: 299 299 |
677 | Ciprofloxacin hydrochloride | 1件: Ciprofloxacin Ciprofloxacin | 2件: D00186
D00186
,
D02216
| - | - | 2件: 96 96, 299 |
678 | CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE | 1件: Ciprofloxacin Ciprofloxacin | 2件: D00186
D00186
,
D02216
| - | - | 1件: 299 299 |
679 | Ciprofloxacin Inhale | 1件: Ciprofloxacin Ciprofloxacin | 2件: D00186
D00186
,
D02216
| - | - | 1件: 299 299 |
680 | Ciprofloxacina | - | - | - | - | 1件: 299 299 |
681 | CIPROFLOXACINA CLORIDRATO | - | - | - | - | 1件: 299 299 |
682 | Ciproxin | - | - | - | - | 1件: 299 299 |
683 | CIPROXIN - 500 MG COMPRESSE RIVESTITE 14 COMPRESSE | - | - | - | - | 1件: 299 299 |
684 | Ciproxin Suspension | - | - | - | - | 1件: 299 299 |
685 | CIPROXIN*6CPR RIV 500MG | - | - | - | - | 1件: 299 299 |
686 | Circadin | 1件: Melatonin Melatonin | 1件: D08170
D08170
| 2件: MTNR1A MTNR1A, MTNR1B 💬 | 2件: Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | 3件: 6 6, 13, 90 |
687 | Circadin ( INN= Melatonin) | 1件: Melatonin Melatonin | 1件: D08170
D08170
| 2件: MTNR1A MTNR1A, MTNR1B 💬 | 2件: Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
688 | Circadin 2 mg | 1件: Melatonin Melatonin | 1件: D08170
D08170
| 2件: MTNR1A MTNR1A, MTNR1B 💬 | 2件: Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | 1件: 90 90 |
689 | CIRCADIN 2 mg comprimidos de liberación prolongada | 1件: Melatonin Melatonin | 1件: D08170
D08170
| 2件: MTNR1A MTNR1A, MTNR1B 💬 | 2件: Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | 1件: 90 90 |
690 | Circadin® | 1件: Melatonin Melatonin | 1件: D08170
D08170
| 2件: MTNR1A MTNR1A, MTNR1B 💬 | 2件: Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 |
691 | Cis-4-Hydroxy-L-Proline | 1件: Proline Proline | 1件: D00035
D00035
| - | - | 1件: 94 94 |
692 | CISAPRIDE | 1件: Cisapride Cisapride | 2件: D00274
D00274
,
D02092
| 3件: HTR2A HTR2A, HTR3A, HTR4 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
693 | Cisplatin | 1件: Cisplatin Cisplatin | 1件: D00275
D00275
| - | - | 1件: 28 28 |
694 | Cistanche Total Glycosides | - | - | - | - | 1件: 2 2 |
695 | Citalopram | 1件: Citalopram Citalopram | 2件: D00822
D00822
,
D07704
| 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 7件: 6 6, 8, 13, 18, 46, 98, 127 |
696 | Citalopram 20mg | 1件: Citalopram Citalopram | 2件: D00822
D00822
,
D07704
| 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 6 6 |
697 | Citicolin | - | - | - | - | 1件: 6 6 |
698 | CITICOLIN*1G/4ML IM IV 5 F | - | - | - | - | 1件: 6 6 |
699 | Citicolina | 1件: Citicoline Citicoline | 1件: D00057
D00057
| - | - | 1件: 6 6 |
700 | Citicolina 1000 mg/die | 1件: Citicoline Citicoline | 1件: D00057
D00057
| - | - | 1件: 6 6 |
701 | CITICOLINA SODICA | 1件: Citicoline Citicoline | 1件: D00057
D00057
| - | - | 1件: 6 6 |
702 | CITOCHINE ED IMMUNOMODULATORI | - | - | - | - | 1件: 13 13 |
703 | Citocoline | - | - | - | - | 1件: 205 205 |
704 | Citric acid | 1件: Citric acid Citric acid | 2件: D00037
D00037
,
D01222
| - | - | 2件: 53 53, 291 |
705 | Citric Acid based Mouthwash | 1件: Citric acid Citric acid | 2件: D00037
D00037
,
D01222
| - | - | 1件: 53 53 |
706 | Citrulline | 1件: Citrulline Citrulline | 1件: D07706
D07706
| - | - | 2件: 86 86, 113 |
707 | CJH1 (CLR4001) | - | - | - | - | 1件: 6 6 |
708 | CJNJ-68150420-ZZZ-G001 (ACT- 064992D) | - | - | - | - | 1件: 86 86 |
709 | CJNJ-68150420-ZZZ-G001 (ACT-064992D) | - | - | - | - | 1件: 86 86 |
710 | CJNJ-68150420-ZZZ-G001(ACT-064992D) | - | - | - | - | 1件: 86 86 |
711 | CK-2017357 | - | - | - | - | 1件: 2 2 |
712 | CK-2017357 (Part A) | - | - | - | - | 1件: 2 2 |
713 | CK-2017357 (Part B) | - | - | - | - | 1件: 2 2 |
714 | CK-2127107 | 1件: Reldesemtiv Reldesemtiv | 1件: D11363
D11363
| 1件: TNNC2 TNNC2 💬 | 1件: Calcium signaling pathway Calcium signaling pathway 💬 | 1件: 2 2 |
715 | CK-3773274 | - | - | - | - | 1件: 58 58 |
716 | CK-3773274 (10 - 30 mg) | - | - | - | - | 1件: 58 58 |
717 | CK-3773274 (5 - 15 mg) | - | - | - | - | 1件: 58 58 |
718 | CK-3773274 (5 - 20 mg) | - | - | - | - | 1件: 58 58 |
719 | CK-3773274 (5 mg, 10 mg, 15 mg and 20 mg) | - | - | - | - | 1件: 58 58 |
720 | CK-3773274 - Granules in Capsule | - | - | - | - | 1件: 58 58 |
721 | CK-3773274 - Tablets | - | - | - | - | 1件: 58 58 |
722 | CK2017357 | - | - | - | - | 1件: 2 2 |
723 | CKD-374 5mg Tab. | - | - | - | - | 1件: 46 46 |
724 | CKD-504 | - | - | - | - | 1件: 8 8 |
725 | CKD-506 | - | - | - | - | 1件: 46 46 |
726 | CLA | - | - | - | - | 1件: 97 97 |
727 | CLA (Chlorogenic acid) | 1件: Chlorogenic Acid Chlorogenic Acid | - | - | - | 1件: 97 97 |
728 | CLADRIBINA | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
729 | Cladribina oral | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
730 | CLADRIBINE | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 3件: 11 11, 13, 94 |
731 | Cladribine (MAVENCLAD®) | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
732 | Cladribine 3.5 mg/kg | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
733 | Cladribine 5.25 mg/kg | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
734 | Cladribine Oral Tablet | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
735 | Cladribine Tablet | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
736 | Cladribine Tablets | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
737 | Cladrybine | - | - | - | - | 1件: 11 11 |
738 | Clarithromycin | 1件: Clarithromycin Clarithromycin | 1件: D00276
D00276
| - | - | 8件: 6 6, 63, 84, 96, 97, 222, 228, 299 |
739 | Clarithromycin (Not used as of 4/2020) | 1件: Clarithromycin Clarithromycin | 1件: D00276
D00276
| - | - | 1件: 6 6 |
740 | Claritromycin | - | - | - | - | 1件: 299 299 |
741 | Claritromycin 500mg film coated tablets | - | - | - | - | 1件: 299 299 |
742 | Clarium 50 mg Retardtabletten | - | - | - | - | 1件: 6 6 |
743 | Clartihromycin, amoxicillin, and omeprazole | 2件: Amoxicillin Amoxicillin, Omeprazole | 7件: D00229
D00229
,
D00455
,
D01207
,
D02925
,
D05259
,
D05261
,
D07452
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 6 6 |
744 | Classic DMARDs treatment group | - | - | - | - | 1件: 46 46 |
745 | Classical ketogenic diet | - | - | - | - | 1件: 137 137 |
746 | Clasteon | 1件: Clodronic acid Clodronic acid | 2件: D03544
D03544
,
D03545
| - | - | 1件: 274 274 |
747 | Clavulanate | 1件: Clavulanic acid Clavulanic acid | 1件: D07711
D07711
| - | - | 1件: 299 299 |
748 | CLAVULANIC ACID | 1件: Clavulanic acid Clavulanic acid | 1件: D07711
D07711
| - | - | 1件: 299 299 |
749 | CLAZAKIZUMAB | 1件: Clazakizumab Clazakizumab | 1件: D10312
D10312
| - | - | 1件: 46 46 |
750 | CLBS12 | - | - | - | - | 1件: 47 47 |
751 | CLE | - | - | - | - | 1件: 6 6 |
752 | Clemastine | 1件: Clemastine Clemastine | 2件: D00666
D00666
,
D03535
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
753 | CLEMASTINE FUMARATE | 1件: Clemastine Clemastine | 2件: D00666
D00666
,
D03535
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
754 | Clemastine Milstein 1 mg, tabletten | 1件: Clemastine Clemastine | 2件: D00666
D00666
,
D03535
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
755 | Clemizole | 1件: Clemizole Clemizole | - | - | - | 1件: 140 140 |
756 | Clenbuterol | 1件: Clenbuterol Clenbuterol | 1件: D07713
D07713
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 4件: 1 1, 2, 6, 256 |
757 | Clenbuterol HCl | 1件: Clenbuterol Clenbuterol | 1件: D07713
D07713
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
758 | CLENBUTEROL HYDROCHLORIDE | 1件: Clenbuterol Clenbuterol | 1件: D07713
D07713
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
759 | Clindamycin | 1件: Clindamycin Clindamycin | 4件: D00277
D00277
,
D01073
,
D01990
,
D02132
| - | - | 2件: 46 46, 299 |
760 | CliniMACS | - | - | - | - | 2件: 60 60, 65 |
761 | CliniMACS device | - | - | - | - | 2件: 60 60, 285 |
762 | CliniMACS Prodigy System | - | - | - | - | 1件: 285 285 |
763 | CliniMACS® CD34 Reagent System cell sorter device | - | - | - | - | 1件: 65 65 |
764 | Clipper | - | - | - | - | 1件: 97 97 |
765 | Clipper 30 cpr 5mg R.M. | - | - | - | - | 1件: 97 97 |
766 | CLIPPER*30CPR 5MG R.M. | - | - | - | - | 1件: 97 97 |
767 | Clobazam | 1件: Clobazam Clobazam | 1件: D01253
D01253
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 2件: 140 140, 144 |
768 | Clobazam High Dose | 1件: Clobazam Clobazam | 1件: D01253
D01253
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 144 144 |
769 | Clobazam Low Dose | 1件: Clobazam Clobazam | 1件: D01253
D01253
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 144 144 |
770 | Clobazam Medium Dose | 1件: Clobazam Clobazam | 1件: D01253
D01253
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 144 144 |
771 | Clobazam PhEur | 1件: Clobazam Clobazam | 1件: D01253
D01253
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 144 144 |
772 | Clobazam Tablets | 1件: Clobazam Clobazam | 1件: D01253
D01253
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 144 144 |
773 | Clobazam Tablets 10mg | 1件: Clobazam Clobazam | 1件: D01253
D01253
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 144 144 |
774 | Clobazam Tablets 20mg | 1件: Clobazam Clobazam | 1件: D01253
D01253
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 144 144 |
775 | Clobazam Tablets 5mg | 1件: Clobazam Clobazam | 1件: D01253
D01253
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 144 144 |
776 | Clobetasol | 1件: Clobetasol Clobetasol | 1件: D07715
D07715
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 4件: 39 39, 46, 51, 162 |
777 | Clobetasol 0.05% ointment | 1件: Clobetasol Clobetasol | 1件: D07715
D07715
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 39 39 |
778 | Clobetasol 0.05% Topical Ointment | 1件: Clobetasol Clobetasol | 1件: D07715
D07715
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 |
779 | Clobetasol Propionate | 2件: Clobetasol Clobetasol, Clobetasol propionate | 2件: D01272
D01272
,
D07715
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 46 46, 162 |
780 | Clobetasol propionate + Methotrexate | 3件: Clobetasol Clobetasol, Clobetasol propionate, Methotrexate | 4件: D00142
D00142
,
D01272
,
D02115
,
D07715
| 3件: DHFR DHFR, DHFR2, NR3C1 💬 | 6件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, Neuroactive ligand-receptor interaction, One carbon pool by folate 💬 | 1件: 162 162 |
781 | Clobetasol propionate alone | 2件: Clobetasol Clobetasol, Clobetasol propionate | 2件: D01272
D01272
,
D07715
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 |
782 | Clobetasol Propionate cream treatment | 2件: Clobetasol Clobetasol, Clobetasol propionate | 2件: D01272
D01272
,
D07715
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 |
783 | Clofarabine | 1件: Clofarabine Clofarabine | 1件: D03546
D03546
| 3件: POLA1 POLA1, POLA2, RRM1 💬 | 6件: DNA replication DNA replication, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 9件: 19 19, 20, 40, 46, 49, 60, 96, 234, 326 |
784 | CLOFAZIMINE | 1件: Clofazimine Clofazimine | 1件: D00278
D00278
| - | - | 1件: 96 96 |
785 | Clomiphene | 1件: Clomifene Clomifene | 2件: D00962
D00962
,
D07726
| 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 74 74 |
786 | Clomiphene citrate | 1件: Clomifene Clomifene | 2件: D00962
D00962
,
D07726
| 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 74 74 |
787 | Clonazepam | 1件: Clonazepam Clonazepam | 1件: D00280
D00280
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 6 6 |
788 | Clonidin | 1件: Clonidine Clonidine | 2件: D00281
D00281
,
D00604
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 78 78 |
789 | Clonidina | 1件: Clonidine Clonidine | 2件: D00281
D00281
,
D00604
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 78 78 |
790 | CLONIDINA CLORIDRATO | 1件: Clonidine Clonidine | 2件: D00281
D00281
,
D00604
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 78 78 |
791 | Clonidine | 1件: Clonidine Clonidine | 2件: D00281
D00281
,
D00604
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 4件: 6 6, 65, 70, 78 |
792 | Clonidine (Catapressan) | 1件: Clonidine Clonidine | 2件: D00281
D00281
,
D00604
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
793 | Clonidine HCl CF 0,150 mg, tabletten | 1件: Clonidine Clonidine | 2件: D00281
D00281
,
D00604
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 78 78 |
794 | Clonidine hydrochloride | 1件: Clonidine Clonidine | 2件: D00281
D00281
,
D00604
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 2件: 6 6, 78 |
795 | Clonidinhydrochlorid | - | - | - | - | 1件: 65 65 |
796 | Clopidogrel | 1件: Clopidogrel Clopidogrel | 4件: D00769
D00769
,
D07729
,
D10823
,
D10824
| 1件: P2RY12 P2RY12 💬 | 1件: Platelet activation Platelet activation 💬 | 2件: 49 49, 86 |
797 | Clorfenamina | 1件: Chlorpheniramine Chlorpheniramine | 4件: D00665
D00665
,
D00668
,
D07398
,
D07803
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 14 14 |
798 | CLORFENAMINA MALEATO | 1件: Chlorpheniramine Chlorpheniramine | 4件: D00665
D00665
,
D00668
,
D07398
,
D07803
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 14 14 |
799 | Cloruro de Sodio | - | - | - | - | 1件: 228 228 |
800 | CLORURO SODICO 7% | - | - | - | - | 1件: 299 299 |
801 | Clostridium botulinum | 1件: Clostridium botulinum Clostridium botulinum | - | - | - | 1件: 13 13 |
802 | CLOSTRIDIUM BOTULINUM TOXIN TYPE A | 2件: Botulinum toxin type A Botulinum toxin type A, Clostridium botulinum | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
803 | Clotrimazole | 1件: Clotrimazole Clotrimazole | 1件: D00282
D00282
| - | - | 1件: 97 97 |
804 | CLOZAPINE | 1件: Clozapine Clozapine | 1件: D00283
D00283
| 11件: ADRA2A ADRA2A, ADRA2B, ADRA2C, DRD4, HTR2A, HTR2C, HTR3A, HTR3B, HTR3C, HTR3D, HTR3E 💬 | 8件: Calcium signaling pathway Calcium signaling pathway, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
805 | CLS | - | - | - | - | 3件: 2 2, 46, 71 |
806 | CLS Brevius stem with Kinectiv technology | - | - | - | - | 1件: 46 46 |
807 | CLTX-305 | - | - | - | - | 1件: 235 235 |
808 | Cluvot | - | - | - | - | 1件: 288 288 |
809 | CM-101 | - | - | - | - | 1件: 94 94 |
810 | CMAB008 | - | - | - | - | 1件: 46 46 |
811 | CME-LEM4 | - | - | - | - | 1件: 117 117 |
812 | CMK389 | - | - | - | - | 1件: 84 84 |
813 | CNC | - | - | - | - | 1件: 85 85 |
814 | CNM-Au8 | - | - | - | - | 2件: 2 2, 13 |
815 | CNP-104 | - | - | - | - | 1件: 93 93 |
816 | Cnp-MS-0601 | - | - | - | - | 1件: 13 13 |
817 | CNS10-NPC implantation | - | - | - | - | 1件: 90 90 |
818 | CNSA-001 | - | - | - | - | 1件: 240 240 |
819 | CNT-02 | - | - | - | - | 1件: 160 160 |
820 | CNTO 1275 | - | - | - | - | 2件: 13 13, 96 |
821 | CNTO 136 | - | - | - | - | 2件: 41 41, 46 |
822 | CNTO 136 100 mg | - | - | - | - | 1件: 46 46 |
823 | CNTO 136 25 mg | - | - | - | - | 1件: 46 46 |
824 | CNTO 136 50 mg | - | - | - | - | 1件: 46 46 |
825 | CNTO 136 IgG | - | - | - | - | 1件: 46 46 |
826 | CNTO 148 | - | - | - | - | 4件: 46 46, 84, 97, 271 |
827 | CNTO 148 (Golimumab) | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 |
828 | CNTO 1959 | - | - | - | - | 1件: 46 46 |
829 | CNTO 1959 + MTX (Group 4) | - | - | - | - | 1件: 46 46 |
830 | CNTO 1959 + MTX (Group 5) | - | - | - | - | 1件: 46 46 |
831 | CNTO 1959 IgG | - | - | - | - | 1件: 46 46 |
832 | CNTO 2476 | - | - | - | - | 1件: 90 90 |
833 | CNTO 328 | - | - | - | - | 1件: 331 331 |
834 | CNTO 6785 100 mg | - | - | - | - | 1件: 46 46 |
835 | CNTO 6785 15 mg | - | - | - | - | 1件: 46 46 |
836 | CNTO 6785 200 mg | - | - | - | - | 1件: 46 46 |
837 | CNTO 6785 50 mg | - | - | - | - | 1件: 46 46 |
838 | CNTO 888 1 mg/kg | - | - | - | - | 1件: 85 85 |
839 | CNTO 888 15 mg/kg | - | - | - | - | 1件: 85 85 |
840 | CNTO 888 5 mg/kg | - | - | - | - | 1件: 85 85 |
841 | CNTO-148 | - | - | - | - | 1件: 97 97 |
842 | CNTO1275 | - | - | - | - | 6件: 46 46, 49, 84, 93, 96, 97 |
843 | CNTO136 | - | - | - | - | 1件: 46 46 |
844 | CNTO148 | - | - | - | - | 4件: 46 46, 84, 97, 107 |
845 | CNTO1959 | - | - | - | - | 4件: 37 37, 41, 96, 97 |
846 | CNTO312 | - | - | - | - | 1件: 97 97 |
847 | CNTO328 | - | - | - | - | 1件: 331 331 |
848 | CNTO6785 | - | - | - | - | 1件: 46 46 |
849 | CNTO888 | - | - | - | - | 1件: 85 85 |
850 | CO | - | - | - | - | 6件: 6 6, 13, 53, 70, 85, 149 |
851 | CO-14 | - | - | - | - | 1件: 13 13 |
852 | Co-medication: Synthetic DMARDs | - | - | - | - | 1件: 46 46 |
853 | CO-TRIMOXAZOLE | - | - | - | - | 1件: 85 85 |
854 | CoA | - | - | - | - | 1件: 120 120 |
855 | Coagadex | 1件: Coagulation factor X human Coagulation factor X human | - | - | - | 1件: 288 288 |
856 | Coagulación factor VIII | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 |
857 | Coagulation factor VIII | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 |
858 | Coagulation factor X | 1件: Coagulation factor X human Coagulation factor X human | - | - | - | 1件: 288 288 |
859 | Coagulation factor XIII | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 288 288 |
860 | Coamoxiclav | - | - | - | - | 1件: 97 97 |
861 | Coarse wheat bran | 2件: Wheat Wheat, Wheat bran | 1件: D06902
D06902
| - | - | 1件: 6 6 |
862 | Cobalt | 1件: Cobalt Cobalt | - | - | - | 1件: 46 46 |
863 | Cobalt™ Bone Cement | 1件: Cobalt Cobalt | - | - | - | 1件: 46 46 |
864 | Cobamamide | 1件: Cobamamide Cobamamide | 1件: D00042
D00042
| - | - | 1件: 299 299 |
865 | Cobimetinib | 1件: Cobimetinib Cobimetinib | 1件: D10405
D10405
| 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 280 280 |
866 | Cobiprostone | 1件: Cobiprostone Cobiprostone | 1件: D08893
D08893
| - | - | 1件: 46 46 |
867 | COBITOLIMOD | 1件: Cobitolimod Cobitolimod | - | - | - | 1件: 97 97 |
868 | Cobitolimod 250 mg | 1件: Cobitolimod Cobitolimod | - | - | - | 1件: 97 97 |
869 | Cobitolimod 500 mg | 1件: Cobitolimod Cobitolimod | - | - | - | 1件: 97 97 |
870 | Cocoa | 1件: Cocoa Cocoa | - | - | - | 1件: 6 6 |
871 | Coconut | 1件: Coconut Coconut | - | - | - | 3件: 13 13, 53, 226 |
872 | Coconut oil | 2件: Coconut Coconut, Coconut oil | 1件: D05326
D05326
| - | - | 2件: 13 13, 226 |
873 | Coconut oil and epigallocatechin gallate | 4件: Coconut Coconut, Coconut oil, Epigallocatechin, Epigallocatechin gallate | 1件: D05326
D05326
| - | - | 1件: 13 13 |
874 | Cod | - | - | - | - | 1件: 46 46 |
875 | Cod liver oil | 1件: Cod liver oil Cod liver oil | 1件: D03578
D03578
| - | - | 1件: 46 46 |
876 | Coenzym Q10 Nanodispersion | - | - | - | - | 1件: 5 5 |
877 | Coenzym Q10, Ubiquinon, Ubichinon | - | - | - | - | 1件: 5 5 |
878 | Coenzyme Q | - | - | - | - | 1件: 13 13 |
879 | Coenzyme Q-10 | 1件: Ubidecarenone Ubidecarenone | 1件: D01065
D01065
| - | - | 1件: 86 86 |
880 | Coenzyme Q-10 in Normal Control subjects | 1件: Ubidecarenone Ubidecarenone | 1件: D01065
D01065
| - | - | 1件: 86 86 |
881 | Coenzyme Q-10 in Pulmonary Hypertension subjects | 1件: Ubidecarenone Ubidecarenone | 1件: D01065
D01065
| - | - | 1件: 86 86 |
882 | Coenzyme Q10 | 1件: Ubidecarenone Ubidecarenone | 1件: D01065
D01065
| - | - | 12件: 2 2, 5, 6, 8, 10, 18, 46, 57, 113, 193, 214, 215 |
883 | Coenzyme Q10 and Lisinopril | 2件: Lisinopril Lisinopril, Ubidecarenone | 3件: D00362
D00362
,
D01065
,
D08131
| 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 1件: 113 113 |
884 | Coenzyme Q10 Nanodispersion (Nanoquinone) | 1件: Ubidecarenone Ubidecarenone | 1件: D01065
D01065
| - | - | 1件: 6 6 |
885 | Coenzyme Q10 with vitamin E | 2件: Ubidecarenone Ubidecarenone, Vitamin E | 2件: D01065
D01065
,
D02331
| - | - | 1件: 6 6 |
886 | CoenzymeQ10 | - | - | - | - | 1件: 21 21 |
887 | CoFactor | - | - | - | - | 3件: 6 6, 265, 288 |
888 | Cofactor supplementation (thiamine, riboflavin, L-carnitine) | 3件: Levocarnitine Levocarnitine, Riboflavin, Thiamine | 7件: D00050
D00050
,
D01622
,
D01913
,
D02030
,
D02176
,
D04713
,
D08580
| - | - | 1件: 265 265 |
889 | Coffee | 1件: Arabica coffee bean Arabica coffee bean | - | - | - | 2件: 96 96, 97 |
890 | COFFEE COAL | 1件: Arabica coffee bean Arabica coffee bean | - | - | - | 1件: 97 97 |
891 | Cogane | - | - | - | - | 1件: 6 6 |
892 | Cogane™ (PYM50028) | - | - | - | - | 1件: 6 6 |
893 | Cohort 1 0.225g | - | - | - | - | 1件: 240 240 |
894 | Cohort 1: 1.0 x 10^8 PolyTregs | - | - | - | - | 1件: 35 35 |
895 | Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 |
896 | Cohort 1:Nilotinib Oral Capsules (150mg or 300mg) | 1件: Nilotinib Nilotinib | 1件: D08953
D08953
| 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 |
897 | Cohort 2 0.75g | - | - | - | - | 1件: 240 240 |
898 | Cohort 2: 2.5x10^8 PolyTregs | - | - | - | - | 1件: 35 35 |
899 | Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 |
900 | Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1) | 1件: Nilotinib Nilotinib | 1件: D08953
D08953
| 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 |
901 | Cohort 3 2.25 g | - | - | - | - | 1件: 240 240 |
902 | Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 |
903 | COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin | - | - | - | - | 1件: 36 36 |
904 | COLAL PRED | - | - | - | - | 1件: 97 97 |
905 | COLAL-PRED | - | - | - | - | 1件: 97 97 |
906 | COLAL-PRED® | - | - | - | - | 1件: 97 97 |
907 | Colazide | - | - | - | - | 1件: 97 97 |
908 | COLCHICINA | 1件: Colchicine Colchicine | 1件: D00570
D00570
| 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 2 2 |
909 | COLCHICINA LIRCA - 1 MG COMPRESSE 60 COMPRESSE | 1件: Colchicine Colchicine | 1件: D00570
D00570
| 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 2 2 |
910 | Colchicine | 1件: Colchicine Colchicine | 1件: D00570
D00570
| 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 7件: 2 2, 42, 46, 56, 93, 210, 266 |
911 | Colchicine 1 MG Oral Tablet | 1件: Colchicine Colchicine | 1件: D00570
D00570
| 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 2 2 |
912 | Colchicine sprinkle capsules | 1件: Colchicine Colchicine | 1件: D00570
D00570
| 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 266 266 |
913 | Cold Cadioplegia | - | - | - | - | 1件: 215 215 |
914 | COLECALCIFEROL | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 4件: 13 13, 46, 96, 228 |
915 | COLECALCIFEROL CONCENTRATE (OILY FORM) | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 13 13 |
916 | Colecalciferol D3 (Vigantol Oil) | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 |
917 | Colectomy | - | - | - | - | 1件: 97 97 |
918 | Colesevelam | 1件: Colesevelam Colesevelam | 2件: D03582
D03582
,
D07743
| - | - | 2件: 96 96, 260 |
919 | Colestipol | 1件: Colestipol Colestipol | 2件: D02113
D02113
,
D07771
| - | - | 1件: 254 254 |
920 | COLESTYRAMINE | 1件: Cholestyramine Cholestyramine | - | - | - | 1件: 254 254 |
921 | Colimicina | - | - | - | - | 1件: 299 299 |
922 | COLIMICINA - 1000000 U/4 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE1 FLACONCINO POLVERE + 1 FIALA SOLVENTE 4 ML | - | - | - | - | 1件: 299 299 |
923 | Colimycine | - | - | - | - | 1件: 299 299 |
924 | COLIMYCINE inhalation | - | - | - | - | 1件: 299 299 |
925 | COLIMYCINE injectable | - | - | - | - | 1件: 299 299 |
926 | COLISTIMETATO SODICO | - | - | - | - | 1件: 299 299 |
927 | Colistimethat-Natrium | - | - | - | - | 1件: 299 299 |
928 | COLISTIMETHATE | 1件: Colistimethate Colistimethate | 1件: D02049
D02049
| - | - | 1件: 299 299 |
929 | Colistimethate 75 mg inhaled two times daily | 1件: Colistimethate Colistimethate | 1件: D02049
D02049
| - | - | 1件: 299 299 |
930 | COLISTIMETHATE SODIUM | 1件: Colistimethate Colistimethate | 1件: D02049
D02049
| - | - | 1件: 299 299 |
931 | COLISTIMETHATE SODIUM (A COMPONENT) | 1件: Colistimethate Colistimethate | 1件: D02049
D02049
| - | - | 1件: 299 299 |
932 | Colistimethate sodium (BAN, USAN), Colistimethatum natricum, Colistin sodium methanesulfonate | 2件: Colistimethate Colistimethate, Colistin | 3件: D02049
D02049
,
D02138
,
D07746
| - | - | 1件: 299 299 |
933 | Colistimethate sodium (promixin) | 1件: Colistimethate Colistimethate | 1件: D02049
D02049
| - | - | 1件: 299 299 |
934 | COLISTIN | 1件: Colistin Colistin | 2件: D02138
D02138
,
D07746
| - | - | 1件: 299 299 |
935 | Colistin CF | 1件: Colistin Colistin | 2件: D02138
D02138
,
D07746
| - | - | 1件: 299 299 |
936 | Colistin Forest - Trockenstechampullen mit Lösungsmittel | 1件: Colistin Colistin | 2件: D02138
D02138
,
D07746
| - | - | 1件: 299 299 |
937 | COLISTIN MESILATE SODIUM | 1件: Colistin Colistin | 2件: D02138
D02138
,
D07746
| - | - | 1件: 299 299 |
938 | Colistineb | - | - | - | - | 1件: 299 299 |
939 | COLISTINEB 2MUI | - | - | - | - | 1件: 299 299 |
940 | Collagenase | 1件: Collagenase clostridium histolyticum Collagenase clostridium histolyticum | 1件: D09596
D09596
| - | - | 1件: 162 162 |
941 | Collect of 10 ml of peripheric blood for DNA extraction | - | - | - | - | 1件: 46 46 |
942 | Collection of blood and urine | - | - | - | - | 1件: 25 25 |
943 | Collection of samples | - | - | - | - | 4件: 49 49, 65, 95, 107 |
944 | Collection of samples of blood and urine | - | - | - | - | 1件: 167 167 |
945 | Colobreathe | 1件: Colistimethate Colistimethate | 1件: D02049
D02049
| - | - | 1件: 299 299 |
946 | Colomycin | - | - | - | - | 1件: 299 299 |
947 | Colonoscopic fecal microbiota material (colo-FMT) | - | - | - | - | 1件: 96 96 |
948 | Colonoscopy | - | - | - | - | 1件: 97 97 |
949 | Colony-purified Bacteroides thetaiotaomicron (B.theta) | - | - | - | - | 1件: 96 96 |
950 | Colorectal biopsies | - | - | - | - | 1件: 97 97 |
951 | ColoVit capsule | - | - | - | - | 1件: 96 96 |
952 | Coltect | - | - | - | - | 1件: 97 97 |
953 | Combination | - | - | - | - | 1件: 46 46 |
954 | Combination antiviral therapy | - | - | - | - | 1件: 93 93 |
955 | Combination fish oil and borage seed oil | 1件: Fish oil Fish oil | - | - | - | 1件: 46 46 |
956 | Combination injection of EPO and G-CSF | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 6 6 |
957 | Combination of a single dose anti-CD20 antibody and bortezomib | 1件: Bortezomib Bortezomib | 1件: D03150
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 61 61 |
958 | Combination of DMARDs | - | - | - | - | 1件: 107 107 |
959 | Combination of fish oil and colesevelam | 2件: Colesevelam Colesevelam, Fish oil | 2件: D03582
D03582
,
D07743
| - | - | 1件: 260 260 |
960 | Combination of Minocycline and MTX or MTX alone | 1件: Minocycline Minocycline | 2件: D00850
D00850
,
D05045
| - | - | 1件: 46 46 |
961 | Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine | 3件: Azathioprine Azathioprine, Dexamethasone, Rituximab | 12件: D00238
D00238
,
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
,
D02994
,
D03033
| 2件: MS4A1 MS4A1, NR3C1 💬 | 2件: Hematopoietic cell lineage Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬 | 1件: 35 35 |
962 | Combination of thrombopoietin mimetic and cyclosporin A | 2件: Cyclosporine Cyclosporine, Thrombopoietin | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 |
963 | Combination Oral Budesonide and Rectal Hydrocortisone | 2件: Budesonide Budesonide, Hydrocortisone | 2件: D00088
D00088
,
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
964 | Combination Product: | - | - | - | - | 1件: 86 86 |
965 | Combination Product: 68Ga-DOTATATE PET/CT | 2件: Dotatate Dotatate, Dotatate gallium Ga-68 | - | - | - | 1件: 238 238 |
966 | Combination Product: Active treatment with dual therapy | - | - | - | - | 1件: 2 2 |
967 | Combination Product: Beclomethasone dipropionate in addition to MC-EVOO | 1件: Beclomethasone dipropionate Beclomethasone dipropionate | 2件: D00689
D00689
,
D07495
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
968 | Combination Product: Beclomethasone dipropionate in addition to refined oil | 1件: Beclomethasone dipropionate Beclomethasone dipropionate | 2件: D00689
D00689
,
D07495
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
969 | Combination Product: Belimumab | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
970 | Combination Product: continuous oral delivery of levodopa/carbidopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
971 | Combination Product: EGCG + Nintedanib | 2件: Epigallocatechin gallate Epigallocatechin gallate, Nintedanib | 1件: D10481
D10481
| 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 |
972 | Combination Product: EGCG + Pirfenidone | 2件: Epigallocatechin gallate Epigallocatechin gallate, Pirfenidone | 1件: D01583
D01583
| 6件: CCL2 CCL2, IL10, IL1A, IL1B, IL6, TNF 💬 | 84件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Chemokine signaling pathway, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 85 85 |
973 | Combination Product: Exercise, and methotrexate | 1件: Methotrexate Methotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 |
974 | Combination Product: Goldic serum | - | - | - | - | 1件: 70 70 |
975 | Combination Product: high MCT formula | - | - | - | - | 1件: 296 296 |
976 | Combination Product: Hyperbaric Oxygen Therapy- | 1件: Oxygen Oxygen | 1件: D00003
D00003
| - | - | 1件: 226 226 |
977 | Combination Product: Implantable System for Remodulin (treprostinil) | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
978 | Combination Product: L-dopa 140 mg | 1件: Levodopa Levodopa | 1件: D00059
D00059
| 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
979 | Combination Product: L-dopa 35 mg | 1件: Levodopa Levodopa | 1件: D00059
D00059
| 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
980 | Combination Product: L-dopa 70mg | 1件: Levodopa Levodopa | 1件: D00059
D00059
| 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
981 | Combination Product: L-dopa 70mg/carbidopa 7mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
982 | Combination Product: Laser, exercise, and methotrexate | 1件: Methotrexate Methotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 |
983 | Combination Product: mavrilimumab | 1件: Mavrilimumab Mavrilimumab | 1件: D09930
D09930
| 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 41 41 |
984 | Combination Product: Methotrexate | 1件: Methotrexate Methotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 |
985 | Combination Product: ND0612 Solution for SC infusion | - | - | - | - | 1件: 6 6 |
986 | Combination Product: ofatumumab with AI | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
987 | Combination Product: ofatumumab with PRF | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
988 | Combination Product: PRP combined Magnovision | - | - | - | - | 1件: 90 90 |
989 | Combination Product: Sanacoach Parkinson (SCP) | - | - | - | - | 1件: 6 6 |
990 | Combination Product: TransCon PTH | - | - | - | - | 1件: 235 235 |
991 | Combination Product: Treprostinil via implanted pump | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
992 | Combination Product: Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator | 2件: Acetate Acetate, Hydrocortisone | 1件: D00088
D00088
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
993 | Combination Steroid | - | - | - | - | 1件: 46 46 |
994 | Combination therapy with vigabatrin and prednisolone | 2件: Prednisolone Prednisolone, Vigabatrin | 9件: D00472
D00472
,
D00535
,
D00980
,
D00981
,
D00982
,
D01239
,
D01998
,
D02156
,
D03301
| 2件: ABAT ABAT, NR3C1 💬 | 8件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Neuroactive ligand-receptor interaction, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 145 145 |
995 | Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 85 85 |
996 | COMBIVIR | 1件: Zidovudine Zidovudine | 1件: D00413
D00413
| - | - | 1件: 265 265 |
997 | Combivir (zidovudine [AZT] / lamivudine [3TC]) | 2件: Lamivudine Lamivudine, Zidovudine | 2件: D00353
D00353
,
D00413
| - | - | 1件: 265 265 |
998 | Comirnaty | 1件: Pfizer-BioNTech COVID-19 Vaccine Pfizer-BioNTech COVID-19 Vaccine | 1件: D11971
D11971
| - | - | 5件: 13 13, 46, 51, 53, 299 |
999 | Comirnaty concentrate for dispersion for injection | 1件: Pfizer-BioNTech COVID-19 Vaccine Pfizer-BioNTech COVID-19 Vaccine | 1件: D11971
D11971
| - | - | 2件: 53 53, 299 |
1000 | Comirnaty Konzentrat zur Herstellung einer Injektionsdispersion | 1件: Pfizer-BioNTech COVID-19 Vaccine Pfizer-BioNTech COVID-19 Vaccine | 1件: D11971
D11971
| - | - | 1件: 13 13 |
1001 | Commercial Formulation Etanercept | 1件: Etanercept Etanercept | 1件: D00742
D00742
| 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
1002 | Commercial Ventavis® (iloprost) | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
1003 | Common Name: Sialic Acid | - | - | - | - | 1件: 30 30 |
1004 | Companion diagnostic ( CDx) | - | - | - | - | 1件: 51 51 |
1005 | Companion diagnostic (CDx) | - | - | - | - | 1件: 96 96 |
1006 | Companion Diagnostic (CDx) Testing | - | - | - | - | 1件: 97 97 |
1007 | Comparator: carbidopa | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
1008 | Comparator: diclofenac | 1件: Diclofenac Diclofenac | 3件: D00903
D00903
,
D00904
,
D07816
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 |
1009 | Comparator: Diclofenac sodium | 1件: Diclofenac Diclofenac | 3件: D00903
D00903
,
D00904
,
D07816
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 |
1010 | Comparator: ezetimibe | 1件: Ezetimibe Ezetimibe | 1件: D01966
D01966
| 1件: NPC1L1 NPC1L1 💬 | 1件: Fat digestion and absorption Fat digestion and absorption 💬 | 2件: 79 79, 260 |
1011 | Comparator: levodopa | 1件: Levodopa Levodopa | 1件: D00059
D00059
| 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
1012 | Comparator: naproxen tablet 500 mg | 1件: Naproxen Naproxen | 1件: D00118
D00118
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 |
1013 | COMPLEMENT C1 ESTERASE INHIBITOR | 1件: Conestat alfa Conestat alfa | 1件: D10845
D10845
| 3件: C1R C1R, C1S, KLKB1 💬 | 6件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, Pertussis, Phagosome, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 61 61 |
1014 | Compound 1a | - | - | - | - | 2件: 246 246, 299 |
1015 | COMPOUND 21 | - | - | - | - | 1件: 85 85 |
1016 | Compound thrombosis capsule sig: 1.5g/tid | - | - | - | - | 1件: 90 90 |
1017 | Compressa effervescente 0,5 mg di budesonide per uso orodispersibile | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
1018 | Compressa effervescente 1 mg di budesonide per uso orodispersibile | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
1019 | Computed Tomography | - | - | - | - | 5件: 34 34, 40, 46, 49, 96 |
1020 | COMTAN | 1件: Entacapone Entacapone | 1件: D00781
D00781
| 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 |
1021 | COMTAN 200* 60 CPR 200 MG | 1件: Entacapone Entacapone | 1件: D00781
D00781
| 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 |
1022 | COMTAN® | 1件: Entacapone Entacapone | 1件: D00781
D00781
| 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 |
1023 | Comtan® | - | - | - | - | 1件: 6 6 |
1024 | Comtess | 1件: Entacapone Entacapone | 1件: D00781
D00781
| 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 |
1025 | Comtess® | - | - | - | - | 1件: 6 6 |
1026 | Concentration unit: mg milligram(s) | - | - | - | - | 1件: 254 254 |
1027 | Concerta | - | - | - | - | 1件: 203 203 |
1028 | Conditioned Medium (CM) | - | - | - | - | 1件: 90 90 |
1029 | CONDUIT™ Interbody Platform composed of the EIT (Emerging Implant Technologies) Cellular Titanium® | 1件: Titanium Titanium | - | - | - | 1件: 70 70 |
1030 | Confortid | - | - | - | - | 1件: 225 225 |
1031 | Conivaptan | 1件: Conivaptan Conivaptan | 2件: D01236
D01236
,
D07748
| 2件: AVPR1A AVPR1A, AVPR2 💬 | 5件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption 💬 | 1件: 86 86 |
1032 | Conjugated equine estrogens | 1件: Conjugated estrogens Conjugated estrogens | 2件: D04070
D04070
,
D05987
| - | - | 1件: 49 49 |
1033 | Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d | 1件: Conjugated estrogens Conjugated estrogens | 2件: D04070
D04070
,
D05987
| - | - | 1件: 49 49 |
1034 | Conjugated pneumococcal vaccine (Prevenar) | - | - | - | - | 1件: 65 65 |
1035 | Continuation of azathioprine | 1件: Azathioprine Azathioprine | 2件: D00238
D00238
,
D03033
| - | - | 1件: 49 49 |
1036 | Continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs) | - | - | - | - | 1件: 265 265 |
1037 | Continued Ocrelizumab | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1038 | Continuous Apomorphine infusion | 1件: Apomorphine Apomorphine | 2件: D02004
D02004
,
D07460
| 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
1039 | Continuous Glucose Monitor | 2件: Dextrose, unspecified form Dextrose, unspecified form, Methamidophos | - | - | - | 1件: 65 65 |
1040 | Continuous glucose monitor (CGM) | 2件: Dextrose, unspecified form Dextrose, unspecified form, Methamidophos | - | - | - | 1件: 299 299 |
1041 | Continuous glucose monitoring | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 2件: 75 75, 299 |
1042 | Continuous Glucose Monitoring System (CGMS) | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 1件: 299 299 |
1043 | Continuous infusion Cefepime | 1件: Cefepime Cefepime | 1件: D02376
D02376
| - | - | 1件: 299 299 |
1044 | Continuous infusion Ceftazidime | 1件: Ceftazidime Ceftazidime | 2件: D00921
D00921
,
D07654
| - | - | 1件: 299 299 |
1045 | Continuous infusion Meropenem | 1件: Meropenem Meropenem | 2件: D02222
D02222
,
D08185
| - | - | 1件: 299 299 |
1046 | Continuous infusion Piperacillin tazobactam | 2件: Piperacillin Piperacillin, Tazobactam | 4件: D00466
D00466
,
D00660
,
D02251
,
D08380
| - | - | 1件: 299 299 |
1047 | Continuous infusion Ticarcillin-clavulanate | 2件: Clavulanic acid Clavulanic acid, Ticarcillin | 2件: D07711
D07711
,
D08593
| - | - | 1件: 299 299 |
1048 | Continuous intrajejunal infusion of levodopa-carbidopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
1049 | Continuous Mononuclear Cell Collection (CMNC) | - | - | - | - | 1件: 96 96 |
1050 | Continuous oxygen | 1件: Oxygen Oxygen | 1件: D00003
D00003
| - | - | 1件: 90 90 |
1051 | Continuous Release Dopamine Agonists | 1件: Dopamine Dopamine | 2件: D00633
D00633
,
D07870
| 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
1052 | Continuous Subcutaneous Lisuride Infusion | 1件: Lisuride Lisuride | 2件: D01462
D01462
,
D08132
| 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
1053 | Contrast Enhanced Ultrasound | - | - | - | - | 1件: 96 96 |
1054 | Contrast Enhanced Voiding Urosonography with Urodynamic Testing | - | - | - | - | 1件: 118 118 |
1055 | Contrast sensitivity measurement | - | - | - | - | 1件: 19 19 |
1056 | Control | - | - | - | - | 4件: 6 6, 46, 168, 299 |
1057 | Control group | - | - | - | - | 5件: 2 2, 34, 46, 70, 235 |
1058 | Control Group 0.9% Isotonic Saline | - | - | - | - | 1件: 299 299 |
1059 | Control intervention (no dexamethasone) | 1件: Dexamethasone Dexamethasone | 9件: D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 |
1060 | Control multivitamin | - | - | - | - | 1件: 299 299 |
1061 | Controlled-release levodopa / carbidopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
1062 | Conventional | - | - | - | - | 1件: 63 63 |
1063 | Conventional DMARD combination | - | - | - | - | 1件: 46 46 |
1064 | Conventional DMARDs | - | - | - | - | 1件: 46 46 |
1065 | Conventional drug therapy(expectorant,bronchodilator) | - | - | - | - | 1件: 86 86 |
1066 | Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone) | 6件: Acetate Acetate, Cortisone acetate, Dexamethasone, Hydrocortisone, Prednisolone, Prednisone | 20件: D00088
D00088
,
D00292
,
D00472
,
D00473
,
D00973
,
D00975
,
D00980
,
D00981
,
D00982
,
D01239
,
D01510
,
D01615
,
D01632
,
D01948
,
D01998
,
D02156
,
D02174
,
D02591
,
D02592
,
D03301
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 |
1067 | Conventional medication | - | - | - | - | 1件: 6 6 |
1068 | Conventional surgery | - | - | - | - | 1件: 34 34 |
1069 | Conventional Synthetic DMARD | - | - | - | - | 1件: 46 46 |
1070 | Conventional syringe - BD Ref 309604 | - | - | - | - | 1件: 46 46 |
1071 | Conventional therapy | - | - | - | - | 2件: 67 67, 222 |
1072 | Conventional therapy users for the last 5 years | - | - | - | - | 1件: 271 271 |
1073 | Coozar | - | - | - | - | 1件: 167 167 |
1074 | COP | - | - | - | - | 1件: 13 13 |
1075 | COP-1 | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1076 | COP-1/Copolymer-1 | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1077 | COPAXONE | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1078 | COPAXONE - 20 MG/ML SOLUZIONE INIETTABILE 28 SIRINGHE PRERIEMPITE | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1079 | COPAXONE - 20 MG/ML SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE 30 SIRINGHE | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1080 | COPAXONE - 40 MG/ML SOLUZIONE INIETTABILE IN | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1081 | COPAXONE - 40 MG/ML SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA 12 SIRINGHE PRERIEMPITE DA 1 ML CON AGO | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1082 | Copaxone 20 mg | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1083 | Copaxone 20 mg/ml | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1084 | COPAXONE 20 mg/ml solución inyectable en jeringa precargada | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1085 | Copaxone 20 mg/ml solución para inyección en jeringa precargada | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1086 | Copaxone 20 mg/ml Solution for Injection, pre-filled syringe | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1087 | Copaxone 20 mg/ml, Solution for Injection, pre-filled syringes | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1088 | Copaxone 20mg/ml Solution for Injection, pre-filled syringe | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1089 | Copaxone 40 mg/ml | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1090 | Copaxone 40 mg/ml solution for injection, pre-filled syringe | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1091 | Copaxone subcutaneous injection syringe | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1092 | COPAXONE*SC 28SIR 20MG/ML | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1093 | Copaxone-Teva | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1094 | Copaxone® | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1095 | Copegus | 1件: Ribavirin Ribavirin | 1件: D00423
D00423
| - | - | 1件: 2 2 |
1096 | Copolymer 1 | - | - | - | - | 1件: 13 13 |
1097 | Copolymer-1 | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1098 | Copper | 1件: Copper Copper | - | - | - | 4件: 2 2, 169, 170, 171 |
1099 | COPPER (64CU) CHLORIDE | 2件: Chloride ion Chloride ion, Copper | - | - | - | 1件: 171 171 |
1100 | Copper Histidinate | 1件: Copper Copper | - | - | - | 1件: 169 169 |
1101 | Copper Histidine | 2件: Copper Copper, Histidine | 1件: D00032
D00032
| - | - | 2件: 169 169, 170 |
1102 | CoQ10 | - | - | - | - | 3件: 5 5, 6, 8 |
1103 | COQUN | - | - | - | - | 1件: 90 90 |
1104 | COR-003 | - | - | - | - | 1件: 75 75 |
1105 | Cord blood | - | - | - | - | 1件: 60 60 |
1106 | Cord Blood Infusion | - | - | - | - | 1件: 60 60 |
1107 | Cord blood therapy | 1件: Umbilical Cord Blood Hematopoietic Stem Cells Umbilical Cord Blood Hematopoietic Stem Cells | - | - | - | 2件: 2 2, 6 |
1108 | Cord Blood Transplant | - | - | - | - | 1件: 60 60 |
1109 | Cord Blood Units | - | - | - | - | 1件: 60 60 |
1110 | CordIn | - | - | - | - | 1件: 60 60 |
1111 | Corn | 1件: Corn Corn | - | - | - | 2件: 46 46, 240 |
1112 | Corn oil capsules | 1件: Corn Corn | - | - | - | 1件: 46 46 |
1113 | Corn starch | 1件: Starch, corn Starch, corn | 1件: D05297
D05297
| - | - | 1件: 49 49 |
1114 | Corn/soy oil | 1件: Corn Corn | - | - | - | 1件: 240 240 |
1115 | Cornstarch | 1件: Starch, corn Starch, corn | 1件: D05297
D05297
| - | - | 2件: 90 90, 257 |
1116 | Cornstarch control | 1件: Starch, corn Starch, corn | 1件: D05297
D05297
| - | - | 1件: 90 90 |
1117 | Coronary flow reserve SE | - | - | - | - | 3件: 58 58, 86, 215 |
1118 | CORT125134 | 1件: Relacorilant Relacorilant | 1件: D11336
D11336
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 75 75 |
1119 | Cortancyl | 1件: Prednisone acetate Prednisone acetate | 1件: D08416
D08416
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 3件: 35 35, 41, 162 |
1120 | CORTANCYL 20 mg | 1件: Prednisone acetate Prednisone acetate | 1件: D08416
D08416
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 35 35, 162 |
1121 | Cortancyl ® 1 mg | 1件: Prednisone acetate Prednisone acetate | 1件: D08416
D08416
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 |
1122 | Cortancyl ® 20 mg | 1件: Prednisone acetate Prednisone acetate | 1件: D08416
D08416
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 |
1123 | Cortancyl ® 5 mg | 1件: Prednisone acetate Prednisone acetate | 1件: D08416
D08416
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 |
1124 | Cortecosteroid | - | - | - | - | 1件: 96 96 |
1125 | Cortef | 1件: Hydrocortisone cypionate Hydrocortisone cypionate | 1件: D00976
D00976
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 3件: 6 6, 81, 83 |
1126 | Cortef (hydrocortisone) | 1件: Hydrocortisone Hydrocortisone | 1件: D00088
D00088
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 83 83 |
1127 | Cortef 5 mg | 1件: Hydrocortisone cypionate Hydrocortisone cypionate | 1件: D00976
D00976
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 83 83 |
1128 | Corticoids+ tocilizumab 8mg/Kg/4 weeks | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 |
1129 | Corticosteroid | - | - | - | - | 10件: 13 13, 42, 43, 44, 45, 66, 84, 96, 97, 222 |
1130 | Corticosteroid (CS) | - | - | - | - | 1件: 41 41 |
1131 | Corticosteroid (prednisolone) | 1件: Prednisolone Prednisolone | 8件: D00472
D00472
,
D00980
,
D00981
,
D00982
,
D01239
,
D01998
,
D02156
,
D03301
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 85 85 |
1132 | Corticosteroid and azathioprine | 1件: Azathioprine Azathioprine | 2件: D00238
D00238
,
D03033
| - | - | 4件: 42 42, 43, 44, 45 |
1133 | Corticosteroid and non-biological agents. | - | - | - | - | 1件: 46 46 |
1134 | Corticosteroid or NSAID | - | - | - | - | 1件: 46 46 |
1135 | Corticosteroid treatment (Methylprednisolone or prednisolone) | 2件: Methylprednisolone Methylprednisolone, Prednisolone | 14件: D00407
D00407
,
D00472
,
D00751
,
D00979
,
D00980
,
D00981
,
D00982
,
D01239
,
D01998
,
D02156
,
D03301
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 64 64 |
1136 | Corticosteroids | - | - | - | - | 10件: 41 41, 46, 49, 64, 97, 107, 164, 220, 296, 300 |
1137 | Corticosteroids & tanCART19/20 | - | - | - | - | 1件: 13 13 |
1138 | Corticosteroids (Aprednislon) | - | - | - | - | 1件: 63 63 |
1139 | Corticosteroids (prednisone or prednisolone) | 2件: Prednisolone Prednisolone, Prednisone | 9件: D00472
D00472
,
D00473
,
D00980
,
D00981
,
D00982
,
D01239
,
D01998
,
D02156
,
D03301
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 49 49 |
1140 | Corticosteroids for Systemic Use | - | - | - | - | 1件: 41 41 |
1141 | Corticosteroids only | - | - | - | - | 1件: 97 97 |
1142 | Corticosteroids'therapy | - | - | - | - | 1件: 35 35 |
1143 | Corticotherapy | - | - | - | - | 1件: 66 66 |
1144 | Corticotrophin | 1件: Corticotropin Corticotropin | 1件: D00146
D00146
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 46 46 |
1145 | Corticotrophin 80 units | 1件: Corticotropin Corticotropin | 1件: D00146
D00146
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 46 46 |
1146 | Corticotropin | 1件: Corticotropin Corticotropin | 1件: D00146
D00146
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 9件: 2 2, 13, 46, 75, 78, 81, 84, 205, 222 |
1147 | Corticotropin-releasing hormone | 2件: Corticorelin Corticorelin, Corticotropin | 2件: D00146
D00146
,
D03905
| 3件: CRHR1 CRHR1, CRHR2, MC2R 💬 | 6件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 2件: 75 75, 205 |
1148 | CortimentMMX 9 mg | - | - | - | - | 1件: 97 97 |
1149 | Cortisol | 1件: Hydrocortisone Hydrocortisone | 1件: D00088
D00088
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 81 81, 98 |
1150 | Cortison | - | - | - | - | 1件: 81 81 |
1151 | Cortisone | 1件: Hydrocortisone Hydrocortisone | 1件: D00088
D00088
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 |
1152 | Cortisone acetate | 3件: Acetate Acetate, Cortisone acetate, Hydrocortisone | 2件: D00088
D00088
,
D00973
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 |
1153 | Corynebacterium diphtheriae | 1件: Corynebacterium diphtheriae Corynebacterium diphtheriae | - | - | - | 1件: 11 11 |
1154 | Cosentyx | 1件: Secukinumab Secukinumab | 1件: D09967
D09967
| 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 4件: 41 41, 107, 269, 271 |
1155 | COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 1 SIRINGA PRERIEMPITA | 1件: Secukinumab Secukinumab | 1件: D09967
D09967
| 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 107 107 |
1156 | COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 2 SIRINGHE PRERIEMPITE | 1件: Secukinumab Secukinumab | 1件: D09967
D09967
| 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 107 107 |
1157 | Cosentyx 300 mg solution for injection in pre-filled syringe | 1件: Secukinumab Secukinumab | 1件: D09967
D09967
| 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 41 41 |
1158 | Cosentyx 300mg solution for injection in pre-filled syringe | 1件: Secukinumab Secukinumab | 1件: D09967
D09967
| 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 41 41 |
1159 | Cosentyx® | 1件: Secukinumab Secukinumab | 1件: D09967
D09967
| 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 269 269 |
1160 | Cosintropina acetato | - | - | - | - | 1件: 113 113 |
1161 | CosmoFer | - | - | - | - | 3件: 86 86, 96, 97 |
1162 | CosmoFer 50mg/ml solution for infusion or injection | - | - | - | - | 2件: 96 96, 97 |
1163 | Costicosteroids | - | - | - | - | 1件: 26 26 |
1164 | Cosyntropin | 1件: Tetracosactide Tetracosactide | 1件: D00284
D00284
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 3件: 83 83, 113, 145 |
1165 | Cosyntropin acetate | 2件: Acetate Acetate, Tetracosactide | 1件: D00284
D00284
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 113 113 |
1166 | Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin | 2件: Tetracosactide Tetracosactide, Vigabatrin | 2件: D00284
D00284
,
D00535
| 2件: ABAT ABAT, MC2R 💬 | 12件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, Metabolic pathways, Neuroactive ligand-receptor interaction, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, cAMP signaling pathway 💬 | 1件: 145 145 |
1167 | Cosyntropin Injectable Suspension, 1 mg/mL | 1件: Tetracosactide Tetracosactide | 1件: D00284
D00284
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 145 145 |
1168 | Cotoretigene Toliparvovec | - | - | - | - | 1件: 90 90 |
1169 | Cotrimoxazole | - | - | - | - | 2件: 85 85, 97 |
1170 | Cotton | 1件: Cotton Cotton | - | - | - | 2件: 35 35, 162 |
1171 | Cotton gauze with petrolatum | 2件: Cotton Cotton, Petrolatum | 1件: D05331
D05331
| - | - | 2件: 35 35, 162 |
1172 | COVERSIN | 1件: Nomacopan Nomacopan | 1件: D11473
D11473
| 1件: C5 C5 💬 | 10件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 2件: 62 62, 109 |
1173 | Coversyl | 1件: Perindopril Perindopril | 2件: D00624
D00624
,
D03753
| 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 2件: 19 19, 167 |
1174 | Coversyl (perindopril) | 1件: Perindopril Perindopril | 2件: D00624
D00624
,
D03753
| 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 1件: 167 167 |
1175 | Coversyl PLUS | - | - | - | - | 1件: 19 19 |
1176 | COVID-19 mRNA Vaccine (nucleoside modified) | - | - | - | - | 3件: 13 13, 46, 51 |
1177 | COVID-19 mRNA vaccine (nucleoside-modified) | - | - | - | - | 4件: 13 13, 46, 51, 299 |
1178 | COVID-19 mRNA vaccine Moderna (CX-024414) | - | - | - | - | 4件: 13 13, 46, 51, 299 |
1179 | COVID-19 vaccination | - | - | - | - | 1件: 13 13 |
1180 | COVID-19 vaccine | - | - | - | - | 3件: 46 46, 49, 51 |
1181 | COVID-19 vaccine (Ad26.COV2-S [recombinant]) | - | - | - | - | 1件: 299 299 |
1182 | COVID-19 Vaccine (ChAdOx1-S [recombinant]) | - | - | - | - | 3件: 46 46, 51, 299 |
1183 | COVID-19 Vaccine AstraZeneca | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 3件: 46 46, 51, 53 |
1184 | COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19) | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 3件: 46 46, 51, 299 |
1185 | COVID-19 Vaccine AstraZeneca suspension for injection COVID-19 Vaccine (ChAdOx1-S [recombinant]) | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 1件: 53 53 |
1186 | Covid-19 Vaccine Janssen | 1件: Janssen COVID-19 Vaccine Janssen COVID-19 Vaccine | 1件: D12129
D12129
| - | - | 2件: 53 53, 299 |
1187 | COVID-19 Vaccine Janssen suspension for injection | 1件: Janssen COVID-19 Vaccine Janssen COVID-19 Vaccine | 1件: D12129
D12129
| - | - | 1件: 299 299 |
1188 | COVID-19 Vaccine Janssen suspension for injection COVID-19 vaccine (Ad26.COV2-S [recombinant]) | 1件: Janssen COVID-19 Vaccine Janssen COVID-19 Vaccine | 1件: D12129
D12129
| - | - | 2件: 53 53, 299 |
1189 | COVID-19 Vaccine Moderna | 1件: Moderna COVID-19 Vaccine Moderna COVID-19 Vaccine | 1件: D12114
D12114
| - | - | 4件: 46 46, 51, 65, 299 |
1190 | COVID-19 Vaccine Moderna dispersion for injection | 1件: Moderna COVID-19 Vaccine Moderna COVID-19 Vaccine | 1件: D12114
D12114
| - | - | 1件: 299 299 |
1191 | COVID19 vaccine | - | - | - | - | 1件: 13 13 |
1192 | Cozaar | 1件: Losartan Losartan | 2件: D00357
D00357
,
D08146
| 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 167 167 |
1193 | Cozaar 50 | 1件: Losartan Losartan | 2件: D00357
D00357
,
D08146
| 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 167 167 |
1194 | COZAAR 50 mg comprimidos recubierto con pelicula | 1件: Losartan Losartan | 2件: D00357
D00357
,
D08146
| 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 179 179 |
1195 | COZAAR INICIO 12,5 mg comprimidos recubiertos con pelicula | 1件: Losartan Losartan | 2件: D00357
D00357
,
D08146
| 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 167 167 |
1196 | CP | - | - | - | - | 6件: 6 6, 46, 96, 97, 107, 271 |
1197 | CP 690,550 | - | - | - | - | 1件: 46 46 |
1198 | CP 690550 MR | - | - | - | - | 1件: 46 46 |
1199 | CP- 690 550 | - | - | - | - | 1件: 97 97 |
1200 | CP-195,543 | - | - | - | - | 1件: 46 46 |
1201 | CP-461 | - | - | - | - | 1件: 96 96 |
1202 | CP-690, 550 - 10 | - | - | - | - | 1件: 46 46 |
1203 | CP-690, 550-10 | - | - | - | - | 2件: 97 97, 107 |
1204 | CP-690,500 5 mg | - | - | - | - | 1件: 97 97 |
1205 | CP-690,55-10 | - | - | - | - | 1件: 46 46 |
1206 | CP-690,550 | - | - | - | - | 5件: 46 46, 96, 97, 107, 271 |
1207 | CP-690,550 (tasocitinib) | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
| 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
1208 | CP-690,550 (tofacitinib) | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
| 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 107 |
1209 | CP-690,550 + methotrexate | 1件: Methotrexate Methotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 |
1210 | CP-690,550 10 mg | - | - | - | - | 1件: 97 97 |
1211 | CP-690,550 – 10 | - | - | - | - | 1件: 46 46 |
1212 | CP-690,550-10 | - | - | - | - | 5件: 46 46, 96, 97, 107, 271 |
1213 | CP-690-550 | - | - | - | - | 1件: 46 46 |
1214 | CP-690-550-10 | - | - | - | - | 1件: 107 107 |
1215 | CP-690-550-10 (DMID D1600180) | - | - | - | - | 1件: 107 107 |
1216 | CP690,550 | - | - | - | - | 2件: 46 46, 97 |
1217 | CPHC (carboxy pyrrolidine hexanoyl pyrrolidone carboxylate) | - | - | - | - | 1件: 28 28 |
1218 | CPK850 | - | - | - | - | 1件: 90 90 |
1219 | CPL500036 | - | - | - | - | 1件: 6 6 |
1220 | CPP | - | - | - | - | 1件: 76 76 |
1221 | CPSI-2364 | - | - | - | - | 1件: 96 96 |
1222 | CPX | - | - | - | - | 2件: 215 215, 299 |
1223 | CR 1 | - | - | - | - | 1件: 46 46 |
1224 | CR 2 | - | - | - | - | 1件: 46 46 |
1225 | CR 3 | - | - | - | - | 1件: 46 46 |
1226 | CR002 | 1件: CR002 CR002 | - | - | - | 1件: 299 299 |
1227 | CR002 Liquid API | 1件: CR002 CR002 | - | - | - | 1件: 299 299 |
1228 | CR0686 | - | - | - | - | 1件: 46 46 |
1229 | Cr13C | - | - | - | - | 1件: 113 113 |
1230 | CR6086 | 1件: CR6086 CR6086 | - | - | - | 1件: 46 46 |
1231 | CR6086Z | - | - | - | - | 1件: 46 46 |
1232 | CR845 1.0 mg | - | - | - | - | 1件: 93 93 |
1233 | Cranberry | 1件: Cranberry Cranberry | - | - | - | 1件: 13 13 |
1234 | Cravit | - | - | - | - | 1件: 85 85 |
1235 | CRC (A3384) | - | - | - | - | 3件: 93 93, 297, 338 |
1236 | CRC3357, ZK-355322, Leukoton | - | - | - | - | 1件: 299 299 |
1237 | CRD007 | - | - | - | - | 1件: 113 113 |
1238 | Creapure | - | - | - | - | 1件: 50 50 |
1239 | Creatine | 1件: Creatine Creatine | - | - | - | 16件: 1 1, 2, 3, 5, 6, 8, 13, 15, 21, 46, 49, 50, 113, 156, 201, 256 |
1240 | Creatine Monohydrate | 1件: Creatine Creatine | - | - | - | 4件: 2 2, 8, 113, 156 |
1241 | Creatine-13C | 1件: Creatine Creatine | - | - | - | 1件: 113 113 |
1242 | Creatinine | 1件: Creatinine Creatinine | 1件: D03600
D03600
| - | - | 4件: 2 2, 46, 60, 70 |
1243 | Crema de rapamicina al 1% y excipientes | - | - | - | - | 1件: 157 157 |
1244 | Crema placebo (excipiente) | - | - | - | - | 1件: 157 157 |
1245 | CREON | - | - | - | - | 2件: 298 298, 299 |
1246 | Creon 10.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 |
1247 | Creon 10000 | - | - | - | - | 2件: 298 298, 299 |
1248 | CREON 10000 Capsules | - | - | - | - | 1件: 299 299 |
1249 | Creon 25.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 |
1250 | Creon 25000 | - | - | - | - | 2件: 298 298, 299 |
1251 | Creon 40.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 |
1252 | CREON IR | - | - | - | - | 1件: 299 299 |
1253 | Creon N | - | - | - | - | 1件: 299 299 |
1254 | CREON N 25000 | - | - | - | - | 1件: 299 299 |
1255 | Creon36™ | - | - | - | - | 1件: 298 298 |
1256 | Creon® | - | - | - | - | 1件: 299 299 |
1257 | Creon® (DR/GR) | - | - | - | - | 1件: 299 299 |
1258 | Creon® 25,000 | - | - | - | - | 1件: 299 299 |
1259 | Crestor | 1件: Rosuvastatin Rosuvastatin | 2件: D01915
D01915
,
D08492
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 3件: 49 49, 79, 299 |
1260 | Crestor Film-Coated Tablet | 1件: Rosuvastatin Rosuvastatin | 2件: D01915
D01915
,
D08492
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 79 79 |
1261 | Crestor Tablets (calcium rosuvastatin) Film-Coated tablets | 2件: Calcium Calcium, Rosuvastatin | 2件: D01915
D01915
,
D08492
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 79 79 |
1262 | Crinecerfont | - | - | - | - | 1件: 81 81 |
1263 | Crinecerfont is a novel non-peptide selective corticotropin releasing factor 1 (CRF1 ) receptor antagonist. | 1件: Corticotropin Corticotropin | 1件: D00146
D00146
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 81 81 |
1264 | Crizotinib | 1件: Crizotinib Crizotinib | 1件: D09731
D09731
| 1件: ALK ALK 💬 | 3件: Non-small cell lung cancer Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer 💬 | 1件: 34 34 |
1265 | CRM197 | 1件: Corynebacterium diphtheriae CRM197 protein Corynebacterium diphtheriae CRM197 protein | - | - | - | 3件: 11 11, 13, 46 |
1266 | Crohn's Disease | - | - | - | - | 1件: 96 96 |
1267 | Crohn's disease exclusion diet | - | - | - | - | 1件: 96 96 |
1268 | Crohn's disease exclusion diet (CDED) | - | - | - | - | 1件: 96 96 |
1269 | Crohns Disease Exclusion Diet + PEN | - | - | - | - | 1件: 96 96 |
1270 | Cromoglicate | 1件: Cromoglicic acid Cromoglicic acid | 2件: D00526
D00526
,
D07753
| - | - | 1件: 85 85 |
1271 | Cromoglicato disodico | - | - | - | - | 1件: 85 85 |
1272 | Cromoglycate | 1件: Cromoglicic acid Cromoglicic acid | 2件: D00526
D00526
,
D07753
| - | - | 1件: 85 85 |
1273 | Cromolyn | 1件: Cromoglicic acid Cromoglicic acid | 2件: D00526
D00526
,
D07753
| - | - | 3件: 2 2, 85, 98 |
1274 | Cromolyn sodio (cromoglicato disodico, DSCG) | 1件: Cromoglicic acid Cromoglicic acid | 2件: D00526
D00526
,
D07753
| - | - | 1件: 85 85 |
1275 | Cromolyn Sodium | 1件: Cromoglicic acid Cromoglicic acid | 2件: D00526
D00526
,
D07753
| - | - | 1件: 85 85 |
1276 | Cromolyn sodium [Disodium Cromoglycate] | 1件: Cromoglicic acid Cromoglicic acid | 2件: D00526
D00526
,
D07753
| - | - | 1件: 85 85 |
1277 | Crono Five ambulatory pump | - | - | - | - | 1件: 86 86 |
1278 | CROVALIMAB | 1件: Crovalimab Crovalimab | 1件: D11696
D11696
| 1件: C5 C5 💬 | 10件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 2件: 62 62, 109 |
1279 | CROWN | - | - | - | - | 1件: 96 96 |
1280 | CRx-102 | - | - | - | - | 1件: 46 46 |
1281 | CRx-102 (2.7/180) | - | - | - | - | 1件: 46 46 |
1282 | CRx-102 (2.7/360) | - | - | - | - | 1件: 46 46 |
1283 | CRX-139 | 1件: CRx-139 CRx-139 | - | - | - | 1件: 46 46 |
1284 | CRx-150 | - | - | - | - | 1件: 46 46 |
1285 | CRYOPRESERVED AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH A LENTIVIRAL VECTOR CONTAINING HUMAN SGSH GENE | - | - | - | - | 1件: 19 19 |
1286 | Cryopreserved EFS-ADA LV transduced patient CD34+ cells | - | - | - | - | 1件: 65 65 |
1287 | Cryopreserved G2SCID lentiviral vector transduced patient CD34+ cells | - | - | - | - | 1件: 65 65 |
1288 | Cryostor CS10 | - | - | - | - | 1件: 53 53 |
1289 | Cryosupernatant plasma | - | - | - | - | 1件: 64 64 |
1290 | Crystalline calcium supplements | 1件: Calcium Calcium | - | - | - | 1件: 235 235 |
1291 | Crystalline cholesterol oil-based suspension | 1件: Cholesterol Cholesterol | 1件: D00040
D00040
| - | - | 1件: 310 310 |
1292 | Crysvita (burosumab-twza) Treatment | 1件: Burosumab Burosumab | 1件: D10913
D10913
| 1件: FGF23 FGF23 💬 | 11件: Breast cancer Breast cancer, Calcium signaling pathway, Gastric cancer, MAPK signaling pathway, Melanoma, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton 💬 | 1件: 238 238 |
1293 | CS (corticosteroids) Only | - | - | - | - | 1件: 97 97 |
1294 | CS-0777 tablets | - | - | - | - | 1件: 13 13 |
1295 | CS0159 | - | - | - | - | 1件: 94 94 |
1296 | CS1 Administration | - | - | - | - | 1件: 86 86 |
1297 | CS10BR05 | - | - | - | - | 1件: 17 17 |
1298 | CS20AT04 (allogenic bone marrow derived mesenchymal stem cell) | - | - | - | - | 1件: 49 49 |
1299 | CsA | - | - | - | - | 8件: 19 19, 49, 50, 53, 60, 63, 222, 228 |
1300 | CSCC_ASC(22) | - | - | - | - | 1件: 53 53 |
1301 | CsDMARD(s) | - | - | - | - | 1件: 46 46 |
1302 | CsDMARDs | - | - | - | - | 1件: 46 46 |
1303 | CSF sampling | - | - | - | - | 1件: 13 13 |
1304 | CSL312 | - | - | - | - | 1件: 85 85 |
1305 | CSL787 | - | - | - | - | 1件: 299 299 |
1306 | CSM allogéniques issues de cordons ombilicaux ( MTI-PP) | - | - | - | - | 1件: 49 49 |
1307 | CSs | - | - | - | - | 1件: 107 107 |
1308 | CST-103 | - | - | - | - | 1件: 6 6 |
1309 | CST-107 | - | - | - | - | 1件: 6 6 |
1310 | CST-139 | - | - | - | - | 1件: 6 6 |
1311 | CT Scan | - | - | - | - | 1件: 65 65 |
1312 | CT- P10 | - | - | - | - | 1件: 46 46 |
1313 | CT-G20 | - | - | - | - | 1件: 58 58 |
1314 | CT-P10 | - | - | - | - | 1件: 46 46 |
1315 | CT-P13 | - | - | - | - | 4件: 46 46, 96, 97, 271 |
1316 | CT-P13 SC (Infliximab) | 1件: Infliximab Infliximab | 1件: D02598
D02598
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 97 |
1317 | CT-P17 | - | - | - | - | 1件: 46 46 |
1318 | CT-P17 SC | - | - | - | - | 1件: 46 46 |
1319 | CT-P17 SC AI (adalimumab) | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
1320 | CT103A cells | - | - | - | - | 1件: 13 13 |
1321 | CTI-1601 | - | - | - | - | 1件: 18 18 |
1322 | CTLA4-IgG4m (RG2077) | - | - | - | - | 1件: 49 49 |
1323 | CTLA4Ig | - | - | - | - | 4件: 46 46, 49, 96, 271 |
1324 | CTX-4430 | - | - | - | - | 1件: 299 299 |
1325 | Cu(II)ATSM | - | - | - | - | 2件: 2 2, 6 |
1326 | Cu-64 DOTATATE | 1件: Dotatate Dotatate | - | - | - | 1件: 84 84 |
1327 | Cufence | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 2件: 58 58, 171 |
1328 | Cufence (trientine dihydrochloride) | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 |
1329 | Cultivated oral mucosal epithelial sheet transplantation | - | - | - | - | 2件: 38 38, 162 |
1330 | Culture of lymphoblastoid line from blood sample | - | - | - | - | 1件: 102 102 |
1331 | Cultured allogeneic fibroblasts | - | - | - | - | 1件: 36 36 |
1332 | Cultured Thymus Tissue | - | - | - | - | 1件: 65 65 |
1333 | Cultured Thymus Tissue for Implantation (CTTI) | - | - | - | - | 1件: 65 65 |
1334 | Cultured Thymus Tissue Implantation (CTTI) | - | - | - | - | 1件: 65 65 |
1335 | Cumulative corticosteroid exposure | - | - | - | - | 1件: 49 49 |
1336 | Cupping | - | - | - | - | 1件: 70 70 |
1337 | Cuprimine (penicillamine) | 1件: Penicillamine Penicillamine | 1件: D00496
D00496
| - | - | 1件: 51 51 |
1338 | Cuprior | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 |
1339 | Cuprior 150 mg | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 |
1340 | Cuprior 150 mg film-coated tablets | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 |
1341 | Cuprior 150mg film-coated tablets | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 |
1342 | Cura-100 | - | - | - | - | 1件: 46 46 |
1343 | Curcuma | - | - | - | - | 1件: 96 96 |
1344 | Curcuma Longa | 1件: Turmeric Turmeric | - | - | - | 2件: 96 96, 299 |
1345 | Curcuma Longa Extract | 1件: Turmeric Turmeric | - | - | - | 1件: 299 299 |
1346 | Curcuma Longa Extract cpl formaat 00 23,2 x 8,5 mm 723 mg | 1件: Turmeric Turmeric | - | - | - | 1件: 299 299 |
1347 | CURCUMA LONGA RHIZOMA | 1件: Turmeric Turmeric | - | - | - | 1件: 96 96 |
1348 | Curcumin | 1件: Curcumin Curcumin | - | - | - | 11件: 2 2, 13, 46, 49, 67, 74, 94, 96, 97, 139, 299 |
1349 | Curcumin (Longvida™) | 1件: Curcumin Curcumin | - | - | - | 1件: 46 46 |
1350 | Curcumin supplement | 1件: Curcumin Curcumin | - | - | - | 1件: 49 49 |
1351 | Curosurf | 1件: Poractant alfa Poractant alfa | 1件: D08402
D08402
| - | - | 1件: 211 211 |
1352 | Current lipid-lowering treatment | - | - | - | - | 1件: 79 79 |
1353 | Current marketed FLOLAN (epoprostenol sodium) | 1件: Epoprostenol Epoprostenol | 2件: D00106
D00106
,
D01337
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
1354 | Current treatment of AL-CM | - | - | - | - | 1件: 28 28 |
1355 | Currently available therapy in the community | - | - | - | - | 1件: 51 51 |
1356 | Cushing's syndrome confirmation | - | - | - | - | 1件: 75 75 |
1357 | Cutaneous iontophoresis of treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 51 51 |
1358 | CUTAQUIG | - | - | - | - | 1件: 65 65 |
1359 | CUV1647 | - | - | - | - | 1件: 254 254 |
1360 | CUVITRU | - | - | - | - | 1件: 65 65 |
1361 | Cuvitru 200 mg/ml solution for subcutaneous injection | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 |
1362 | CV-MG01 | - | - | - | - | 1件: 11 11 |
1363 | CVD00118-E | - | - | - | - | 1件: 6 6 |
1364 | CVL-751 | - | - | - | - | 1件: 6 6 |
1365 | CVN424 High Dose | - | - | - | - | 1件: 6 6 |
1366 | CVN424 Low Dose | - | - | - | - | 1件: 6 6 |
1367 | CVT-301 | - | - | - | - | 1件: 6 6 |
1368 | CVT-301 (Dose Level 1) | - | - | - | - | 1件: 6 6 |
1369 | CVT-301 (Dose Level 2) | - | - | - | - | 1件: 6 6 |
1370 | CVT-301 35mg | - | - | - | - | 1件: 6 6 |
1371 | CVT-301 50mg | - | - | - | - | 1件: 6 6 |
1372 | CVT-301 High Dose | - | - | - | - | 1件: 6 6 |
1373 | CVT-301 Low Dose | - | - | - | - | 1件: 6 6 |
1374 | CVT-301, LIP | - | - | - | - | 1件: 6 6 |
1375 | CVXL-0107 | - | - | - | - | 1件: 6 6 |
1376 | CX-016492 | - | - | - | - | 1件: 245 245 |
1377 | CX-017950 | - | - | - | - | 1件: 245 245 |
1378 | CX-4945 oral formulation | - | - | - | - | 1件: 331 331 |
1379 | CX-8998 | - | - | - | - | 1件: 6 6 |
1380 | Cx401 | - | - | - | - | 1件: 96 96 |
1381 | CX501 | 1件: CX501 CX501 | - | - | - | 1件: 36 36 |
1382 | CX516 | 1件: CX516 CX516 | - | - | - | 1件: 206 206 |
1383 | CX516 (Ampalex®) | 1件: CX516 CX516 | - | - | - | 1件: 206 206 |
1384 | Cx601 | - | - | - | - | 1件: 96 96 |
1385 | CXA-10 | 1件: CXA-10 CXA-10 | - | - | - | 2件: 86 86, 222 |
1386 | Cy | - | - | - | - | 1件: 60 60 |
1387 | Cy-ATG | - | - | - | - | 1件: 60 60 |
1388 | CyA | - | - | - | - | 2件: 50 50, 222 |
1389 | CyberKnife | - | - | - | - | 1件: 6 6 |
1390 | CYC | - | - | - | - | 1件: 40 40 |
1391 | CYC202 | - | - | - | - | 1件: 299 299 |
1392 | Cyclo ((diaminoethyl-carbamate)HyPro-Phg-(D) Trp-Ly di-aspartate | 1件: Pasireotide Pasireotide | 1件: D10147
D10147
| 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 |
1393 | Cyclo ((diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Ly di-aspartate | 1件: Pasireotide Pasireotide | 1件: D10147
D10147
| 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 |
1394 | Cyclo((diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Lys-Tyr(Bzl)-Phe) di-aspartate | 1件: Pasireotide Pasireotide | 1件: D10147
D10147
| 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 |
1395 | Cyclo(diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Lys-Tyr(Bzl)-Phe) | 1件: Pasireotide Pasireotide | 1件: D10147
D10147
| 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 |
1396 | CYCLO[L-ALANYL-L-SERYL-L-ISOLEUCYL-L-PROLYL-L-PROLYL-L-GLUTAMINYL-L-LYSYL-L-TYROSYL-D-PROLYL-L-PROLYL-(2S)-2-AMINODECANOYL-L-ALPHA-GLUTAMYL-L-THREONYL] | - | - | - | - | 1件: 299 299 |
1397 | Cyclophosfamide | - | - | - | - | 1件: 13 13 |
1398 | Cyclophosphamid | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 66 66 |
1399 | Cyclophosphamide | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 45件: 11 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 265, 274, 283, 284, 285, 288, 326, 331 |
1400 | Cyclophosphamide (CY) | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 60 60 |
1401 | Cyclophosphamide (CY) (Plan 1) | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 2件: 60 60, 285 |
1402 | Cyclophosphamide (CY) (Plan 2) | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 2件: 60 60, 285 |
1403 | Cyclophosphamide (Cytoxan) | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 65 65 |
1404 | Cyclophosphamide (drug) | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 13 13 |
1405 | Cyclophosphamide + pred | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 283 283 |
1406 | Cyclophosphamide 100mg | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 60 60 |
1407 | Cyclophosphamide 150mg | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 60 60 |
1408 | Cyclophosphamide 30 | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 3件: 65 65, 285, 326 |
1409 | Cyclophosphamide 40 | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 3件: 65 65, 285, 326 |
1410 | Cyclophosphamide 50mg | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 60 60 |
1411 | Cyclophosphamide 50Mg Oral Tablet | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 162 162 |
1412 | Cyclophosphamide and ATG | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 13 13 |
1413 | Cyclophosphamide and fludarabine | 2件: Cyclophosphamide Cyclophosphamide, Fludarabine | 4件: D00287
D00287
,
D01907
,
D07760
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
1414 | Cyclophosphamide and steroids | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 222 222 |
1415 | Cyclophosphamide Dose Level 1 | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 2件: 65 65, 284 |
1416 | Cyclophosphamide Dose Level 2 | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 2件: 65 65, 284 |
1417 | Cyclophosphamide Dose Level 3 | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 2件: 65 65, 284 |
1418 | Cyclophosphamide Dose Level 4 | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 2件: 65 65, 284 |
1419 | Cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids | 3件: Azathioprine Azathioprine, Cyclophosphamide, Methotrexate | 6件: D00142
D00142
,
D00238
,
D00287
,
D02115
,
D03033
,
D07760
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 44 44 |
1420 | Cyclophosphamide Injection 1g | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 3件: 50 50, 51, 52 |
1421 | CYCLOPHOSPHAMIDE MONOHYDRATE | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 4件: 13 13, 60, 96, 256 |
1422 | Cyclophosphamide post transplant | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 65 65 |
1423 | Cyclophosphamide(CTX) | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 224 224 |
1424 | Cyclophosphamide, Azathioprine,prednisone,methylprednisolone | 4件: Azathioprine Azathioprine, Cyclophosphamide, Methylprednisolone, Prednisone | 11件: D00238
D00238
,
D00287
,
D00407
,
D00473
,
D00751
,
D00979
,
D03033
,
D05000
,
D05001
,
D05002
,
D07760
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 3件: 42 42, 43, 45 |
1425 | Cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) | 3件: Bortezomib Bortezomib, Cyclophosphamide, Dexamethasone | 12件: D00287
D00287
,
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
,
D03150
,
D07760
| 2件: NR3C1 NR3C1, PSMB5 💬 | 9件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 |
1426 | Cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen | 3件: Bortezomib Bortezomib, Cyclophosphamide, Dexamethasone | 12件: D00287
D00287
,
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
,
D03150
,
D07760
| 2件: NR3C1 NR3C1, PSMB5 💬 | 9件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 |
1427 | Cyclophosphamide, Bortezomib, dexamethasone | 3件: Bortezomib Bortezomib, Cyclophosphamide, Dexamethasone | 12件: D00287
D00287
,
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
,
D03150
,
D07760
| 2件: NR3C1 NR3C1, PSMB5 💬 | 9件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 |
1428 | Cyclophosphamide, Bortezomib, dexamethasone plus Daratumumab | 4件: Bortezomib Bortezomib, Cyclophosphamide, Daratumumab, Dexamethasone | 13件: D00287
D00287
,
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
,
D03150
,
D07760
,
D10777
| 3件: CD38 CD38, NR3C1, PSMB5 💬 | 16件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Calcium signaling pathway, Hematopoietic cell lineage, Huntington disease, Metabolic pathways, Neuroactive ligand-receptor interaction, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Salivary secretion, Spinocerebellar ataxia 💬 | 1件: 28 28 |
1429 | Cyclophosphamide, Fludarabine | 2件: Cyclophosphamide Cyclophosphamide, Fludarabine | 4件: D00287
D00287
,
D01907
,
D07760
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 285 285 |
1430 | Cyclophosphamide, fludarabine , thymoglobulin | 3件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit), Cyclophosphamide, Fludarabine | 4件: D00287
D00287
,
D01907
,
D07760
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 60 60 |
1431 | Cyclophosphamide, Fludarabine, Rabbit ATG | 4件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit), Cyclophosphamide, Fludarabine, Rabbit | 4件: D00287
D00287
,
D01907
,
D07760
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 60 60 |
1432 | Cyclophosphamide, Fludarabine, Thymoglobulin | 3件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit), Cyclophosphamide, Fludarabine | 4件: D00287
D00287
,
D01907
,
D07760
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 60 60 |
1433 | Cyclophosphamide,Campath IH and TBI | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 60 60 |
1434 | Cyclophosphamide,cyclosporine A | 2件: Cyclophosphamide Cyclophosphamide, Cyclosporine | 3件: D00184
D00184
,
D00287
,
D07760
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 |
1435 | Cyclophosphamide-prednisone-azathioprine | 3件: Azathioprine Azathioprine, Cyclophosphamide, Prednisone | 5件: D00238
D00238
,
D00287
,
D00473
,
D03033
,
D07760
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 49 49 |
1436 | Cyclophosphamide/azathioprine | 2件: Azathioprine Azathioprine, Cyclophosphamide | 4件: D00238
D00238
,
D00287
,
D03033
,
D07760
| - | - | 1件: 44 44 |
1437 | Cyclophosphamide/Glatiramer acetate | 3件: Acetate Acetate, Cyclophosphamide, Glatiramer | 3件: D00287
D00287
,
D04318
,
D07760
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1438 | Cyclophosphamidum | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 44 44 |
1439 | Cyclophosphamidum 500 mg | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 44 44 |
1440 | Cyclosphamine | - | - | - | - | 1件: 85 85 |
1441 | Cyclosporin | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 17件: 38 38, 46, 49, 50, 53, 56, 60, 62, 63, 93, 95, 97, 113, 164, 222, 274, 326 |
1442 | Cyclosporin A | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 11件: 46 46, 49, 53, 56, 60, 62, 63, 93, 95, 113, 164 |
1443 | Cyclosporin A+Glucocorticoids | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 60 60, 62 |
1444 | Cyclosporin, low dose steroid | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 |
1445 | Cyclosporin, Methotrexate (GVHD prophylaxis) | 2件: Cyclosporine Cyclosporine, Methotrexate | 3件: D00142
D00142
,
D00184
,
D02115
| 7件: DHFR DHFR, DHFR2, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 38件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Antifolate resistance, Axon guidance, B cell receptor signaling pathway, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Folate biosynthesis, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Natural killer cell mediated cytotoxicity, One carbon pool by folate, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 326 326 |
1446 | Cyclosporine | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 37件: 11 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 107, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
1447 | Cyclosporine (Gengraf ) | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 |
1448 | Cyclosporine (USAN) | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 97 97 |
1449 | Cyclosporine 0.09% Ophthalmic Solution | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 53 53 |
1450 | Cyclosporine 5 mg/kg bid days 0-14 | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 38 38, 39 |
1451 | Cyclosporine A | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 11件: 19 19, 20, 36, 49, 50, 53, 58, 60, 107, 234, 283 |
1452 | Cyclosporine A (CsA) | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 19 19, 60 |
1453 | Cyclosporine A dry powder inhalation (Drug) | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 |
1454 | Cyclosporine combine with mycophenolate mofetil | 3件: Cyclosporine Cyclosporine, Mycophenolate mofetil, Mycophenolic acid | 5件: D00184
D00184
,
D00752
,
D05094
,
D05095
,
D05096
| 7件: IMPDH1 IMPDH1, IMPDH2, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 36件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Drug metabolism - other enzymes, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Purine metabolism, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 283 283 |
1455 | Cyclosporine Inhalation Solution | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 |
1456 | Cyclosporine Inhalation Solution (CIS) | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 |
1457 | Cyclosporine Oral Product | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 |
1458 | Cyclosporine Pill | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 56 56 |
1459 | CYCLOSPORINE VS INFLIXIMAB | 2件: Cyclosporine Cyclosporine, Infliximab | 2件: D00184
D00184
,
D02598
| 6件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2, TNF 💬 | 86件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amphetamine addiction, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Dopaminergic synapse, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Glucagon signaling pathway, Glutamatergic synapse, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Renin secretion, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, VEGF signaling pathway, Viral protein interaction with cytokine and cytokine receptor, Wnt signaling pathway, Yersinia infection, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 97 97 |
1460 | Cyclosporine-A | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 95 95 |
1461 | Cyclosporins | - | - | - | - | 4件: 53 53, 60, 65, 222 |
1462 | CyCol | - | - | - | - | 1件: 97 97 |
1463 | CyCol™ | - | - | - | - | 1件: 97 97 |
1464 | Cyklokapron® | - | - | - | - | 1件: 46 46 |
1465 | Cyltezo | - | - | - | - | 1件: 96 96 |
1466 | CYMBALTA | - | - | - | - | 3件: 6 6, 13, 49 |
1467 | Cystadane anhydrous | - | - | - | - | 1件: 19 19 |
1468 | CYSTADROPS | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 1件: 19 19 |
1469 | CYSTADROPS 0.55% eye drops, solution | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 1件: 19 19 |
1470 | CYSTAGON | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 3件: 8 8, 19, 299 |
1471 | Cystagon (cysteamine bitartrate) immediate-release capsules | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 1件: 299 299 |
1472 | Cystagon 150mg | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 1件: 19 19 |
1473 | Cystagon 50mg | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 1件: 19 19 |
1474 | Cystagon® | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 1件: 19 19 |
1475 | Cystagon® (Cysteamine Bitartrate) | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 1件: 19 19 |
1476 | Cysteamine | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 4件: 8 8, 19, 21, 299 |
1477 | Cysteamine (mercaptamine) viscous solution | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 1件: 19 19 |
1478 | Cysteamine Bitartrate | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 4件: 8 8, 19, 21, 299 |
1479 | Cysteamine bitartrate (Cystagon) | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 1件: 299 299 |
1480 | Cysteamine bitartrate (INN: mercaptamine bitartrate | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 1件: 19 19 |
1481 | Cysteamine bitartrate (INN: mercaptamine bitartrate ) | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 1件: 19 19 |
1482 | Cysteamine bitartrate (INN: mercaptamine bitartrate) | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 1件: 19 19 |
1483 | Cysteamine Bitartrate Delayed-release Capsules | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 1件: 19 19 |
1484 | Cysteamine Bitartrate Delayed-release Capsules (RP103) | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 1件: 19 19 |
1485 | CYSTEAMINE HYDROCHLORIDE | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 1件: 19 19 |
1486 | Cysteine | 1件: Cysteine Cysteine | 2件: D00026
D00026
,
D02326
| - | - | 11件: 6 6, 13, 19, 34, 84, 85, 88, 90, 254, 296, 310 |
1487 | Cysteine hydrochloride | 1件: Cysteine Cysteine | 2件: D00026
D00026
,
D02326
| - | - | 1件: 254 254 |
1488 | Cystic Fibrosis Ready to Use Supplemental Food | - | - | - | - | 1件: 299 299 |
1489 | Cystoscopic injection of Botox into the urinary bladder | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 6 6 |
1490 | CYT107 | - | - | - | - | 1件: 25 25 |
1491 | Cytarabine | 1件: Cytarabine Cytarabine | 3件: D00168
D00168
,
D03046
,
D03637
| - | - | 7件: 11 11, 13, 14, 25, 49, 60, 65 |
1492 | Cytochrome P450 (CYP) Substrates | - | - | - | - | 2件: 96 96, 97 |
1493 | Cytokine-treated Veto Cells | - | - | - | - | 1件: 60 60 |
1494 | Cytolytic CD4+ T cells | - | - | - | - | 1件: 13 13 |
1495 | Cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant | - | - | - | - | 1件: 62 62 |
1496 | Cytotoxic Combination | - | - | - | - | 1件: 56 56 |
1497 | Cytoxan | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 2件: 60 60, 96 |
1498 | CZP | - | - | - | - | 1件: 46 46 |
1499 | Cápsulas de Laquinimod 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 |
1500 | Células madre mesenquimales | - | - | - | - | 1件: 13 13 |
1501 | Células madre mesenquimales de tejido adiposo autólogo | - | - | - | - | 1件: 2 2 |
1502 | Células madre mesenquimales haploidénticas derivadas de médula ósea | - | - | - | - | 1件: 36 36 |
1503 | Células Mesenquimales de tejido adiposo | - | - | - | - | 1件: 2 2 |
1504 | Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas | - | - | - | - | 1件: 274 274 |
1505 | Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas(ref cruzada PEI nº 12-088) | - | - | - | - | 1件: 274 274 |
1506 | Células mesenquimales troncales adultas autólogas de medula ósea expandidas | - | - | - | - | 1件: 117 117 |
1507 | Células mesenquimales troncales adultas autólogas de médula ósea expandidas | - | - | - | - | 1件: 117 117 |
1508 | Células troncales hematopoyéticas autólogas adultas extraidas de médula ósea | - | - | - | - | 1件: 2 2 |